UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy
Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ý | ||
Filed by a Party other than the Registrant o |
||
Check the appropriate box: |
||
o |
Preliminary Proxy Statement |
|
o |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
ý |
Definitive Proxy Statement |
|
o |
Definitive Additional Materials |
|
o |
Soliciting Material under §240.14a-12 |
Cigna Corporation | ||||
(Name of Registrant as Specified In Its Charter) |
||||
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
||||
Payment of Filing Fee (Check the appropriate box): |
||||
ý |
No fee required. |
|||
o |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|||
(1) | Title of each class of securities to which transaction applies: |
|||
(2) | Aggregate number of securities to which transaction applies: |
|||
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
|||
(4) | Proposed maximum aggregate value of transaction: |
|||
(5) | Total fee paid: |
|||
o |
Fee paid previously with preliminary materials. |
|||
o |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|||
(1) |
Amount Previously Paid: |
|||
(2) | Form, Schedule or Registration Statement No.: |
|||
(3) | Filing Party: |
|||
(4) | Date Filed: |
2015 ANNUAL MEETING OF SHAREHOLDERS AND PROXY STATEMENT |
CIGNA CORPORATION |
Wednesday, April 22, 2015 at 8:00 A.M.
Windsor Marriott Hotel, Ballroom 4 l 28 Day Hill Road l Windsor, CT 06095
March 13, 2015
900
Cottage Grove Road
Bloomfield, Connecticut 06002
Dear Cigna Shareholder:
On behalf of the Cigna Corporation Board of Directors, our senior leadership team and our Cigna colleagues around the globe, we are pleased to invite you to attend our 2015 Annual Meeting of Shareholders on April 22, 2015. The attached Notice of Annual Meeting of Shareholders and proxy statement contain important information about the business to be conducted at the Annual Meeting.
Over this past year, Cigna's strong financial and operating performance continued. In the face of a challenging and dynamic environment, 2014 represented a fifth consecutive year of delivering competitively attractive financial results for our shareholders. This track record of outstanding results and differentiated shareholder returns continues to be driven by Cigna's global mission and the disciplined execution of our strategy. We continue to effectively invest in our capabilities and expand our offerings in new and existing geographies while driving innovation to deliver value to the market, including new incentive programs with our engaged customers and providers.
We are positioning our company to grow and win in a rapidly changing market environment. By embracing change and leveraging our four critical capabilities insights, localization, personalization and talent we will drive value creation over the long-term. Our ability to leverage these differentiated capabilities across our Company, effectively deploy capital, and take advantage of new and emerging market opportunities, are the forces behind our goal of doubling our revenues over the next seven to eight years.
In this proxy statement, you will find more detail on our pay-for-performance philosophy. Our compensation program ensures that the interests of Cigna's executives are well aligned with the goals of our Company through a reward and incentive program based on disciplined measures of Company and individual performance.
We believe that strong corporate governance provides the foundation for financial integrity, shareholder confidence and attractive performance. During 2014, we continued our commitment to strong corporate governance practices, with a Board of Directors that is diverse in terms of its composition, skills and experience and a Board self-assessment that was conducted by an independent third party.
Your vote is very important. Whether or not you plan to attend the Annual Meeting, we hope that you will vote as soon as possible. Please review the instructions on each of your voting options described in the Important Notice Regarding the Availability of Proxy Materials. Additional instructions on how to vote can be found on pages 7 through 10 of the proxy statement.
We look forward to seeing you at the 2015 Annual Meeting. As always, thank you for your continued support of Cigna.
Sincerely, | ||
/s/ David M. Cordani David M. Cordani President and Chief Executive Officer |
/s/ Isaiah Harris, Jr. Isaiah Harris, Jr. Chairman of the Board |
NOTICE OF 2015 ANNUAL MEETING OF SHAREHOLDERS
Date and Time: | Wednesday, April 22, 2015 at 8:00 a.m. | |
Place: |
Windsor Marriott Hotel, Ballroom 4 28 Day Hill Road Windsor, Connecticut 06095 |
|
Items of Business: |
Proposal 1: Election of the three director nominees for terms expiring in April 2018. |
|
Proposal 2: Advisory approval of executive compensation. |
||
Proposal 3: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2015. |
||
Consideration of any other business properly brought before the meeting. |
||
Record Date: |
Monday, February 23, 2015. Only Cigna shareholders of record at the close of business on the record date are entitled to receive this notice and vote at the meeting and any adjournment or postponement of the meeting. |
|
Proxy Voting: |
Your vote is very important, regardless of the number of shares you own. We urge you to promptly vote by telephone, by using the Internet, or, if you received a proxy card or instruction form, by completing, dating, signing and returning it by mail. For instructions on voting, please see Questions and Answers about Voting beginning on page 7. |
March 13, 2015 | ||
By order of the Board of Directors, | ||
/s/ Neil Boyden Tanner Neil Boyden Tanner Corporate Secretary |
Important Notice Regarding the Availability of
Proxy Materials for the Annual Meeting of Shareholders
To Be Held on April 22, 2015
The
Notice of Annual Meeting, Proxy Statement and Annual Report for
the fiscal year ended December 31, 2014 are available at www.envisionreports.com/ci.
TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
We provide below highlights of certain information in this proxy statement. This is only a summary please refer to the complete proxy statement and 2014 annual report before you vote.
MISSION AND STRATEGY
Cigna's mission is to improve the health, well-being and sense of security of the people we serve in our more than 85 million customer relationships around the globe. This mission and focus on delivering value for our customers is at the center of what we do every day. Creating value for our customers, and in turn, our shareholders, is a direct result of the effective execution of our Go Deep, Go Global, Go Individual strategy that we implemented in 2010.
We believe that our success in executing our strategy in 2014 and during the past several years provides a strong foundation from which we can continue to deliver competitively attractive earnings, revenue growth and free cash flow that can be deployed to create additional value for Cigna shareholders. To achieve our goals, we have built a guiding framework around three components: leveraging our core capabilities in existing businesses; effectively deploying capital; and pursuing new and emerging opportunities. We continue to invest in new capabilities, personalize our product and service offerings, and expand our geographic footprint. We believe that our guiding framework will continue to drive differentiated value for our customers and shareholders.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 1
|
PROXY STATEMENT SUMMARY (CONTINUED)
BUSINESS PERFORMANCE
In 2014, Cigna delivered its fifth consecutive year of competitively attractive financial results. Consolidated revenue increased 8% over 2013 to $34.9 billion, with each business segment delivering strong growth. Consolidated adjusted income from operations* increased to $2.0 billion compared with $1.93 billion for 2013. This reflects strong revenue growth, continued effective medical cost management and disciplined expense management. The following charts illustrate our track record of consistent growth.
* We encourage you to review our Annual Report on Form 10-K for the year ended December 31, 2014 for more complete financial information. Consolidated adjusted income from operations is the principal measure we use to assess profitability but it is not a financial measure calculated in accordance with generally accepted accounting principles in the United States (GAAP). For a reconciliation of consolidated adjusted income from operations to the most directly comparable GAAP financial measure, which is shareholders' net income, see Annex A.
TOTAL SHAREHOLDER RETURN
The chart below shows our TSR as of December 31, 2014, on a one-, three- and five-year basis. For Cigna's TSR relative to its current peer group and the S&P 500 Index, see page 43. In addition, in 2014, we repurchased 18.5 million shares of our stock for approximately $1.6 billion.
Total Shareholder Return
2
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
PROXY STATEMENT SUMMARY (CONTINUED)
BOARD OF DIRECTORS
Current Directors |
|
Age | Occupation | Current Term Expiration | Committee Memberships | | |||||||
| | | | | | | | | | | | | |
Isaiah Harris, Jr. | 62 | Former President and Chief Executive Officer of AT&T Advertising & Publishing East | 2016 | Chairman of the Board Executive (Chair) |
|||||||||
| David M. Cordani | | 49 | President and Chief Executive Officer of Cigna | 2016 | Executive | | ||||||
Eric J. Foss | 56 | Chairman, President and Chief Executive Officer of ARAMARK Corporation | 2017 | Corporate Governance People Resources |
|||||||||
Michelle D. Gass | | 46 | Chief Customer Officer of Kohl's Corporation | 2017 |
Audit Corporate Governance |
| |||||||
Jane E. Henney, M.D. | 67 | Former Senior Vice President, Provost and Professor of Medicine, University of Cincinnati College of Medicine | 2016 | Corporate Governance (Chair) Executive People Resources |
|||||||||
Roman Martinez IV | | 67 | Private Investor | 2017 |
Audit Finance |
| |||||||
John M. Partridge | 65 | Former President of Visa, Inc. | 2015 | Executive Finance (Chair) People Resources |
|||||||||
James E. Rogers | | 67 | Former Chairman, President and Chief Executive Officer of Duke Energy Corporation | 2015 |
Audit Finance |
| |||||||
Eric C. Wiseman | 59 | Chairman, President and Chief Executive Officer of VF Corporation | 2015 | Finance People Resources |
|||||||||
Donna F. Zarcone | | 57 | President and Chief Executive Officer of The Economic Club of Chicago | 2016 |
Audit (Chair) Executive Finance |
| |||||||
William D. Zollars | 67 | Former Chairman, President and Chief Executive Officer of YRC Worldwide, Inc. | 2017 | Executive Corporate Governance People Resources (Chair) |
|||||||||
| | | | | | | | | | | | | |
CORPORATE GOVERNANCE
Cigna is committed to ensuring strong corporate governance practices on behalf of our shareholders. We believe that strong corporate governance provides the foundation for financial integrity, shareholder confidence and attractive performance.
Our key governance practices include:
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 3
|
PROXY STATEMENT SUMMARY (CONTINUED)
EXECUTIVE COMPENSATION
Cigna's executive compensation program is based on the philosophy that executive pay should strongly align with the interests of our shareholders, directly link to Company and individual performance, and attract and retain executive talent. We believe the achievement of our corporate goals will result in the creation of meaningful and sustained long-term value for our shareholders. In 2014, our shareholders overwhelmingly cast advisory votes in favor of our executive compensation program, with 94.7% of votes cast in favor.
The primary principles underlying our compensation philosophy are to:
The target pay mix for the Chief Executive Officer and the other named executive officers during 2014 reflects these principles, as shown in the charts below. The percentages shown below are targets only and will not match the percentages calculable from the compensation reflected in the Summary Compensation Table on page 73.
4
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
PROXY STATEMENT SUMMARY (CONTINUED)
VOTING MATTERS AND BOARD RECOMMENDATIONS
| | | | | | |
|
Proposals |
Board's Recommendation | | |||
|
Proposal 1. Election of Directors. The Board and the Corporate Governance Committee believe that the three director nominees, John M. Partridge, James E. Rogers and Eric C. Wiseman, bring a combination of qualifications, skills and experience that is required for a well-rounded Board. Each director nominee has proven leadership ability, good judgment and has been an active and valued participant on the Board during his tenure. |
FOR each of the |
||||
| | | | | | |
|
Proposal 2. Advisory Approval of Executive Compensation. The Board believes that Cigna's executive compensation program design effectively aligns the interests of our executive officers with those of our shareholders by tying a significant portion of their compensation to Cigna's performance and rewarding our executive officers for the creation of long-term value for Cigna's shareholders. Because your vote is advisory, it will not be binding upon the Board. However, the Board and People Resources Committee value your opinion and will review and consider the voting results when making future executive compensation decisions. |
FOR |
||||
| | | | | | |
|
Proposal 3. Ratification of the Appointment of PriceWaterhouseCoopers LLP as our Independent Registered Accounting Firm for 2015. The Audit Committee approved the appointment of PricewaterhouseCoopers LLP as Cigna's independent registered public accounting firm for 2015. The Audit Committee and the Board believe that the continued retention of PricewaterhouseCoopers LLP to serve as the Company's independent registered public accounting firm is in the best interests of the Company and its shareholders. As a matter of good corporate governance, the Board is seeking shareholder ratification of the appointment. |
FOR |
||||
| | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 5
|
INFORMATION ABOUT THE 2015 ANNUAL MEETING
QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS
Why did I receive proxy materials? What is included in the proxy materials? |
Our Board of Directors is soliciting your proxy to vote at the 2015 Annual Meeting of Shareholders. You received proxy materials because you owned shares of Cigna common stock on February 23, 2015, the record date, and that entitles you to vote at the Annual Meeting.
Proxy materials include the notice of annual meeting of shareholders, the proxy statement and our annual report on Form 10-K for the year ended December 31, 2014. If you received paper copies, the proxy materials also include a proxy card or voting instruction form. The proxy statement describes the matters on which the Board of Directors would like you to vote, and provides information about Cigna that we must disclose under Securities and Exchange Commission (SEC) regulations when we solicit your proxy.
Your proxy will authorize specified persons, each of whom also are referred to as a proxy, to vote on your behalf at the Annual Meeting. By use of a proxy, you can vote whether or not you attend the meeting in person. The written document by which you authorize a proxy to vote on your behalf is referred to as a proxy card.
Why did I receive a "Notice of the Internet Availability of Proxy Materials" instead of printed copies of the proxy statement and annual report? |
Cigna has elected to take advantage of the SEC's rule that allows us to furnish proxy materials to you online. On March 13, 2015, we mailed to shareholders a notice of the Internet availability of proxy materials containing instructions on how to access our proxy materials online. We believe electronic delivery will lower costs and reduce the environmental impact of our Annual Meeting because we will print and mail fewer full sets of materials.
You may request to receive printed proxy materials by following the instructions contained in the notice of Internet availability. You also may contact Cigna Shareholder Services at the address listed on page 99.
How can I get electronic access to the proxy materials? |
The proxy materials are available for viewing at www.envisionreports.com/ci. The notice of Internet availability of proxy materials also provides instructions on how to:
For shareholders who received a printed copy of our materials, you still may choose to receive proxy materials electronically in the future. If you choose to do so, you will receive an email with instructions containing electronic links to the proxy materials for next year's annual meeting and the proxy voting site.
If you hold your shares through a bank, broker or other custodian, you also may have the opportunity to receive the proxy materials electronically. Please check the information contained in the documents provided to you by your bank, broker or other custodian.
We encourage you to take advantage of the availability of the proxy materials electronically to help reduce the environmental impact of the Annual Meeting.
6
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
INFORMATION ABOUT THE 2015 ANNUAL MEETING (CONTINUED)
QUESTIONS AND ANSWERS ABOUT VOTING
What am I voting on at the Annual Meeting? |
Proposal |
Item |
Board's Vote Recommendation |
Page |
|
||||||
1 | Election of the three director nominees named in this proxy statement for terms expiring in April 2018 | Vote FOR each of the nominees | 11 | |||||||
2 |
Advisory approval of executive compensation |
Vote FOR |
40 |
|
||||||
3 |
Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2015 |
Vote FOR |
91 |
|||||||
| | | | | | | | | | |
Could other matters be decided at the Annual Meeting? |
We are not aware of any other matters that will be presented and voted upon at the Annual Meeting. The proxies will have discretionary authority, to the extent permitted by law, to decide how to vote on other matters that may come before the Annual Meeting.
How many votes can be cast by all shareholders? |
Each share of Cigna common stock is entitled to one vote on each of the three directors to be elected and one vote on each of the other matters properly presented at the Annual Meeting. We had 258,518,549 shares of common stock outstanding and entitled to vote on February 23, 2015.
How many votes must be present to hold the Annual Meeting? |
At least two-fifths of the issued and outstanding shares entitled to vote, or 103,407,420 shares, present in person or by proxy, are needed for a quorum to hold the Annual Meeting. Abstentions and broker non-votes (discussed below) are included in determining whether a quorum is present. We urge you to vote by proxy even if you plan to attend the Annual Meeting. This will help us know that enough votes will be present to hold the meeting.
How many votes are needed to approve each proposal? How do abstentions or broker non-votes affect the voting results? |
The following table summarizes the vote threshold required for approval of each proposal and the effect on the outcome of the vote of abstentions and uninstructed shares held by brokers (referred to as broker non-votes). When a beneficial owner does not provide voting instructions to the institution that holds the shares in street
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 7
|
INFORMATION ABOUT THE 2015 ANNUAL MEETING (CONTINUED)
name, brokers may not vote those shares in matters deemed non-routine. Proposals 1 and 2 below are non-routine matters.
Proposal Number |
Item |
Vote Required for Approval |
Effect of Abstentions |
Effect of Broker Non-Votes |
|
|||||||
1 | Election of directors | Majority of votes cast | No effect | Not voted/No effect | ||||||||
2 |
Advisory approval of executive compensation |
Majority of shares present and entitled to vote |
Counted "against" |
Not voted/No effect |
|
|||||||
3 |
Ratification of the appointment of independent auditor |
Majority of shares present and entitled to vote |
Counted "against" |
No broker non-votes; shares are voted by brokers in their discretion |
||||||||
| | | | | | | | | | | | |
Signed but unmarked proxy cards will be voted "for" proposals 1, 2 and 3. Shares held by the Cigna Stock Fund of the Cigna 401(k) Plan that are not voted timely or properly, will be voted by the plan trustees as instructed by Cigna's Retirement Plan Committee.
How do I vote if I own shares as a record holder? |
If your name is registered on Cigna's shareholder records as the owner of shares, you are the "record holder." If you hold shares as a record holder, there are four ways that you can vote your shares.
Over the Internet. Vote at www.envisionreports.com/ci. The Internet voting system is available 24 hours a day until 11:59 p.m. Eastern Time on Tuesday, April 21, 2015. Once you enter the Internet voting system, you can record and confirm (or change) your voting instructions.
By telephone. Use the telephone number shown on your proxy card. The telephone voting system is available 24 hours a day in the United States until 11:59 p.m. Eastern time on Tuesday, April 21, 2015. Once you enter the telephone voting system, a series of prompts will tell you how to record and confirm (or change) your voting instructions.
By mail. If you received a proxy card, mark your voting instructions on the card and sign, date and return it in the postage-paid envelope provided. If you received only a notice of Internet availability but want to vote by mail, the notice includes instructions on how to request a paper proxy card. For your mailed proxy card to be counted, we must receive it before 8:00 a.m. Eastern Time on Wednesday, April 22, 2015.
In person. Attend the Annual Meeting, or send a personal representative with a valid legal proxy.
Please note that you cannot vote using the notice of Internet availability of proxy materials. The notice identifies the items of business and describes how to vote, but you cannot vote by marking the notice and returning it.
How do I vote if my Cigna shares are held by a bank, broker or custodian? |
If your shares are held by a bank, broker or other custodian (commonly referred to as shares held "in street name"), the holder of your shares will provide you with a copy of this proxy statement, a voting instruction form and directions on how to provide voting instructions. These directions may allow you to vote over the Internet or by telephone. Unless you provide voting instructions, your shares will not be voted on any matter except for ratifying the appointment of our independent auditors. To ensure that your shares are counted in the election of directors and the advisory approval of executive compensation, we encourage you to provide instructions on how to vote your shares.
8
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
INFORMATION ABOUT THE 2015 ANNUAL MEETING (CONTINUED)
If you hold shares in street name and want to vote in person at the Annual Meeting, you will need to ask your bank, broker or custodian to provide you with a valid legal proxy. You will need to bring the proxy with you to the Annual Meeting in order to vote. Please note that if you request a legal proxy from your bank, broker or custodian, any previously executed proxy will be revoked and your vote will not be counted unless you vote in person at the Annual Meeting or appoint another valid legal proxy to vote on your behalf.
How do I vote if my Cigna shares are held by Fidelity or Computershare in an employee stock account? |
Employee stock accounts maintained by Fidelity hold unvested restricted stock. Employee stock accounts maintained by Computershare hold former restricted stock that has vested and shares acquired through an option exercise. You are the record holder of shares in either of these accounts and you should follow the rules above for voting shares held as a record holder.
Can I vote if I have money in the Cigna Stock Fund of the Cigna 401(k) Plan? |
Yes, if you have money invested in the Cigna Stock Fund of the Cigna 401(k) Plan, you may provide voting instructions as to the number of shares allocated to your account on the record date. However, you have an earlier deadline for submitting voting instructions. Your voting instructions must be received by 11:59 p.m. Eastern time on Thursday, April 16, 2015. You may vote over the Internet, by telephone or by mail (as described above), but you may not vote shares allocated to your 401(k) accounts in person at the Annual Meeting. The plan trustees will vote such shares in accordance with your voting instructions if they are received timely. If you do not send instructions by the April 16, 2015 deadline, you do not vote or you return your proxy card with unclear voting instructions or no voting instructions, the plan trustees will vote the number of shares allocated to your 401(k) account as instructed by Cigna's Retirement Plan Committee. Your voting instructions will be kept confidential under the terms of the plan.
Shares allocated to your 401(k) account and shares held in an employee stock account with Fidelity or Computershare may be aggregated on one proxy card. Please note that if voting instructions are submitted after 11:59 p.m. Eastern time on Thursday, April 16, 2015, your vote will be counted for any shares held in your employee stock accounts at Fidelity or Computershare, but not with respect to shares allocated to your 401(k) account.
Can I change my vote? |
Yes. If you are a record holder, you may:
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 9
|
INFORMATION ABOUT THE 2015 ANNUAL MEETING (CONTINUED)
If you hold your shares in street name, you may:
Who will count the votes? Is my vote confidential? |
Computershare has been appointed Inspector of Election for the Annual Meeting. The Inspector of Election will determine the number of shares outstanding, the shares represented at the Annual Meeting, the existence of a quorum, and the validity of proxies and ballots, and will count all votes and ballots.
All votes are confidential. Your voting records will not be disclosed to us, except as required by law, in contested Board elections or certain other limited circumstances.
Who pays for the proxy solicitation and how will Cigna solicit votes? |
Cigna pays the cost of preparing our proxy materials and soliciting your vote. Proxies may be solicited on our behalf by our directors, officers, employees and agents by telephone, electronic or facsimile transmission or in person. We will enlist the help of banks and brokerage houses in soliciting proxies from their customers and reimburse them for their related out-of-pocket expenses. In addition, we have engaged Georgeson, Inc. to assist in soliciting proxies. Cigna will pay Georgeson a fee of approximately $15,000 plus reasonable out-of-pocket expenses.
Where can I find the voting results of the Annual Meeting? |
We will publish the voting results of the Annual Meeting on a Current Report on Form 8-K filed with the SEC. The Form 8-K will be available online at www.cigna.com/aboutus/sec-filings within four business days following the end of our Annual Meeting.
IMPORTANT INFORMATION IF YOU PLAN TO ATTEND THE ANNUAL MEETING IN PERSON
You must be able to show that you owned Cigna's common stock on the record date, February 23, 2015, in order to gain admission to the Annual Meeting. Please bring to the meeting the notice of Internet availability of proxy materials, a printed proxy card or a brokerage statement or letter from your broker verifying ownership of Cigna shares as of February 23, 2015. You also must bring a valid government-issued photo ID. Registration will begin at 7:30 a.m. Please note that you are not permitted to bring any cameras, recording equipment, electronic devices, large bags, briefcases or packages into the Annual Meeting.
10
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS
ELECTION OF DIRECTORS (PROPOSAL 1)
The Board of Directors is elected by Cigna's shareholders. At the Annual Meeting, the Board is nominating for election by shareholders three directors for three-year terms expiring in 2018. The role of the Board, its leadership structure and governance practices are described below in the Governance Policies and Practices section beginning on page 25. This section describes the process for director elections and director nominations, identifies the director responsibilities and qualifications considered by the Board and the Corporate Governance Committee in selecting and nominating directors, and presents the biographies, skills and qualifications of the director nominees and those directors continuing in office.
PROCESS FOR DIRECTOR ELECTIONS
Cigna's Board of Directors is divided into three classes, each with a three-year term. In December 2012, the Board amended Cigna's By-Laws to provide for the phased elimination of the classified board structure. Under the amendment, shareholders will vote on the election of directors whose terms expire in 2016 for one-year terms beginning at the 2016 annual meeting of shareholders. A director (or his or her successor) who has been elected to a three-year term that does not expire at the 2016 annual meeting of shareholders will complete such three-year term, and thereafter will stand for election for a one-year term.
Cigna has adopted a majority voting standard for the election of directors in uncontested elections. Under this standard, each director must receive a majority of the votes cast with respect to that director. This means that the number of votes cast "for" a director nominee must exceed the number of votes cast "against" that nominee for the director to be elected. Each director has agreed to tender, and not withdraw, his or her resignation if he or she does not receive a majority of the votes cast at the Annual Meeting. The Corporate Governance Committee will make a recommendation to the Board on whether to accept the resignation. The Board has discretion to accept or reject the resignation. A director whose resignation is under consideration will not participate in the decisions of the Corporate Governance Committee or the Board concerning his or her resignation. In contested elections, the voting standard is a plurality of votes cast.
PROCESS FOR SELECTING AND NOMINATING DIRECTORS
Director Selection and Nomination Process |
The Corporate Governance Committee retains a third-party search firm to assist in identifying and evaluating candidates for Board membership. The Corporate Governance Committee also considers suggestions for Board nominees submitted by shareholders, which are evaluated using the same criteria as new director candidates and current director nominees.
Once a potential candidate has been identified, the Corporate Governance Committee reviews the background of new director candidates and presents them to the Board for consideration. When considering director candidates and the current composition of the Board, the Corporate Governance Committee and the Board consider how each candidate's background, experiences, skills and/or prior board and committee service will contribute to the diversity of the Board. In addition, the Corporate Governance Committee and the Board consider the Company's business strategy and how each director candidate's background complements that strategy. Candidates interview with the Chair of the Corporate Governance Committee and the Chairman of the Board, as well as other members of the Board, as appropriate.
The Corporate Governance Committee assesses the Board's composition as part of the annual self-evaluation of the Board (described on page 28). When considering whether to nominate current directors for re-election,
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 11
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
the Corporate Governance Committee and the Board review the Board's annual self-evaluation and the individual director's performance against the criteria for Board membership (identified below under Director Expectations and Qualifications). The Board considered its composition as part of its annual evaluation which, for 2014, was led by an independent third party. The Board may nominate for election and appoint to fill vacant or new Board positions only those persons who agree to adhere to the Company's majority voting standard (described above under Process for Director Elections).
Director Expectations and Qualifications |
The Corporate Governance Committee, in consultation with the Board, has identified individual director expectations and qualifications, characteristics, skills and experience that it believes every member of the Board should have. In addition, the Corporate Governance Committee has developed a list of areas of experience that it believes contribute to a well-rounded Board. The Corporate Governance Committee and the Board take into consideration these criteria and the mix of experience as part of the director recruitment, selection, evaluation and nomination process. While the Board does not have a formal policy with regard to diversity, the Corporate Governance Committee works to ensure that the Board is comprised of individuals with expertise in fields relevant to Cigna's business, experience from different professions and industries, a diversity of age, ethnicity, gender and geographic location and a range of tenures to provide a balance of fresh perspective and continuity.
EXPECTATIONS OF EVERY DIRECTOR |
|
|||||
Understand Cigna's businesses and the importance of the creation of shareholder value. Participate in an active, constructive and objective way at Board and committee meetings. Review and understand advance briefing materials. Contribute effectively to the Board's evaluation of executive talent, compensation and succession planning. Consult with and be available to the CEO and senior management. |
Contribute effectively to the Board's assessment of strategy and risk. Share expertise, experience, knowledge and insights as related to the matters before the Board. Advance Cigna's business objectives and reputation. Demonstrate an ongoing commitment to engage with the CEO and senior management outside of Board and committee meetings on matters affecting Cigna. |
|
||||
| | | | | | |
QUALIFICATIONS, CHARACTERISTICS, SKILLS AND EXPERIENCE OF EVERY DIRECTOR |
|
|||||
Good judgment and strong commitment to ethics and integrity. Ability to analyze complex business and public policy issues and provide relevant input concerning strategy. Free of conflicts of interest. |
Ability to assess different risks and impact on shareholder value. Contribution to the overall diversity (in its various forms) of the Board. High degree of achievement in their respective fields. |
|
||||
| | | | | | |
12
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
AREAS OF EXPERIENCE FOR A DIVERSE BOARD |
|
|||||
Business Leader |
Chief executive officer, CEO-equivalent or a business unit leader with profit and loss responsibility for a company or business unit with annual revenues comparable to the revenue threshold for the Fortune 500. |
|||||
Finance |
Leadership position with responsibility for, or oversight of, public company financial reporting processes, capital markets, corporate finance and audit; experience focused on money-management, such as investment banks, credit card companies, consumer finance companies, stock brokerages, investment funds and insurance (other than health care/managed care). |
|||||
|
Marketing and Consumer Insights |
Leadership position with responsibility for, or oversight of, an organization's marketing, advertising or consumer insights function, product development or brand building; experience with organizations where substantially all business is conducted directly with end-user consumers. |
|
|||
International/Global |
Leadership position with non-U.S. responsibilities and experience working outside of the United States. |
|||||
|
Information Technology |
Leadership position in an information technology organization or an organization's information technology function with responsibility for, or oversight of, development, installation, implementation, security or maintenance of computer systems, applications or digital informatics. |
|
|||
Healthcare and Delivery Systems |
Experience with organizations that provide medical and/or health care services, or that seek to reduce health costs to patients through provision of care management and the use of innovative delivery system solutions. |
|||||
|
Regulated Industry/Public Policy |
Experience with organizations whose issues or purpose are largely guided by a regulatory, legislative or public policy framework; experience in government affairs or policy making. |
|
|||
| | | | | | |
Upon the recommendation of the Corporate Governance Committee, the Board is nominating the three directors listed below for re-election for terms to expire in April 2018. All nominees have consented to serve, and the Board does not know of any reason why any nominee would be unable to serve. If a nominee becomes unavailable or unable to serve before the Annual Meeting, the Board may either reduce its size or designate another nominee. If the Board designates a nominee, your proxy will be voted for the substitute nominee.
Below are biographies, skills and qualifications for each of the nominees and for each of the directors continuing in office. Joseph P. Sullivan, who had served as a Cigna director since 2010, retired from the Board in February 2015 consistent with the Board's mandatory retirement age policy. Each of the director nominees currently serves on the Board. The Board believes that the combination of the various experiences, skills and qualifications represented contributes to an effective and well-functioning Board and that the nominees and directors continuing in office possess the qualifications, based on the criteria described above, to provide meaningful oversight of Cigna's business and strategy.
The Board of Directors unanimously recommends that shareholders vote FOR the nominees listed below.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 13
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
John M. Partridge, Former President of Visa, Inc. |
| | | | |
| Mr. Partridge, 65, has served on Cigna's Board since 2009. He currently chairs the Finance Committee and serves on the Executive and People Resources Committees. | | ||
| | | | |
Mr. Partridge served as President of Visa Inc., a publicly traded consumer credit company, from 2009 until 2013 and as Chief Operating Officer from 2007 to 2009. He joined Visa USA in October 1999 and served as President and Chief Executive Officer of Inovant (a Visa subsidiary) from 2000 to 2007 and as Interim President of Visa USA in 2007. From 1998 until joining Visa USA, Mr. Partridge served as Senior Vice President and Chief Information Officer of Unum Provident Corp., a publicly traded disability insurance company. From 1989 to 1998, Mr. Partridge was Executive Vice President for Credicorp Inc., a commercial banking, insurance and investment banking company, where he was responsible for consumer banking, technology and operations. Prior to joining Credicorp Inc., Mr. Partridge held various management positions with Wells Fargo Bank. Mr. Partridge has been a Director of Global Payments, Inc., a publicly traded provider of electronic transaction processing services, since 2013. His current term as a Director of Cigna began in 2012 and expires in 2015.
SKILLS AND QUALIFICATIONS |
Business Leader. Extensive senior leadership experience through his positions with Visa, Inc., Visa USA, Inovant, Unum and Credicorp.
Finance. As President and CEO of Innovant, had direct oversight of financial operations, financial reporting, merger and acquisition activities and corporate restructurings. As President of Visa, involved with financial oversight and reporting and strategic transactions. Responsibilities at Credicorp provided significant financial services experience.
International/Global. As President of Visa, responsibilities included international business leadership. Director of a large public company with extensive international operations. Responsibilities with Credicorp included international assignments.
Information Technology. Experience managing and overseeing information technology investments in support of business objectives gained through each of his executive leadership positions, including as Chief Information Officer of Unum and as a director of Global Payments. As President of Inovant, oversaw Visa's electronic payment processing service.
Marketing and Consumer Insights. Through his tenure with Visa, focused heavily on consumer credit and oversaw marketing, product, client service, support and processing services. As Executive Vice President of Credicorp, responsibilities included consumer banking.
14
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
James E. Rogers, Former Chairman, President and Chief Executive Officer of Duke Energy Corporation |
| | | | |
| Mr. Rogers, 67, has served on Cigna's Board since 2007. He currently serves on the Audit and Finance Committees. | | ||
| | | | |
Mr. Rogers served as Chairman of Duke Energy Corporation, a publicly traded electric power company, from 2007 until 2013 and as the President and Chief Executive Officer from 2006 until 2013. He co-founded and has served as Chairman of Brightlight Foundation, a non-profit provider of globally accessible and affordable energy solutions, since 2011. He was formerly the Chairman, President and Chief Executive Officer of CINERGY Corp. (which merged with Duke Energy Corporation in 2006) from 1994 until 2006. Mr. Rogers has been a Director of Applied Materials, Inc., a publicly traded provider of equipment services and software, since 2008 and served as a director of Fifth Third Bancorp, a regional banking corporation from 1995 until 2009. He received recognition from the National Association of Corporate Directors as an NACD Directorship 100 "Class of 2011" member. His current term as a Director of Cigna began in 2012 and expires in 2015.
SKILLS AND QUALIFICATIONS |
Business Leader. Extensive senior leadership experience through his positions with Duke Energy and in the utility industry for 25 years. Over the course of his career, served on the boards of eight Fortune 500 companies.
Finance. As President of Duke Energy, had oversight of financial operations, financial reporting, merger and acquisition activities and corporate restructurings. As a director of Fifth Third Bancorp, developed expertise in several facets of commercial and consumer financial services.
Regulated Industry/Public Policy. Throughout his career at Duke Energy and CINERGY, operated in a heavily regulated environment and oversaw and implemented strategic policy initiatives. Before his corporate career, served as the Deputy General Counsel for the Federal Energy Regulatory Commission and as a partner in the law firm of Akin Gump Strauss Hauer & Feld in Washington D.C.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 15
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Eric C. Wiseman, Chairman, President and Chief Executive Officer of VF Corporation |
| | | | |
| Mr. Wiseman, 59, has served on Cigna's Board since 2007. He currently serves on the Finance and People Resources Committee. | | ||
| | | | |
Mr. Wiseman has served as Chairman of VF Corporation, a publicly traded apparel and footwear company, since August 2008, as Chief Executive Officer since January 2008, and as President and a Director since 2006. He served as Chief Operating Officer of VF Corporation from 2006 to 2007; Executive Vice President, Global Brands from 2005 to 2006; Vice President and Chairman, Sportswear and Outdoor Coalitions from 2004 until 2005; and Vice President and Chairman, Global Intimates and Sportswear Coalition from 2003 until 2004. Mr. Wiseman has been a Director of Lowe's Companies, Inc., a publicly traded retail home improvement and appliance company, since 2011. His current term as a Director of Cigna began in 2012 and expires in 2015.
SKILLS AND QUALIFICATIONS |
Business Leader. Extensive senior leadership experience through his positions with VF Corporation.
Finance. As Chairman, President and CEO of VF Corporation, has oversight of financial operations, merger and acquisition activities and corporate restructurings.
Marketing and Consumer Insights. Through leadership roles at VF Corporation, oversees
marketing of 30 different brands through all channels of distribution, both domestically and internationally. As a director of Lowe's, focuses on end-user consumer-related issues.
International/Global. Through leadership positions at VF Corporation, oversees operations and product sales in over 150 countries. Prior to joining VF Corporation, held executive leadership roles at Sara Lee Corporation which included international business leadership and international assignments.
16
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
DIRECTORS WHO WILL CONTINUE IN OFFICE
David M. Cordani, President, Chief Executive Officer and Director, Cigna |
| | | | |
| Mr. Cordani, 49, has served on Cigna's Board since 2009. He currently serves on the Executive Committee. | | ||
| | | | |
Mr. Cordani has served as Cigna's Chief Executive Officer since December 2009 and as President since June 2008. He served as Chief Operating Officer from June 2008 until December 2009; President, Cigna HealthCare from 2005 until 2008; and Senior Vice President, Customer Segments & Marketing, Cigna HealthCare from 2004 until 2005. He has been employed by Cigna since 1991. Mr. Cordani has served as a director of General Mills, Inc., a publicly traded global manufacturer and marketer of branded consumer foods, since 2014. His current term as a Director of Cigna began in 2013 and expires in 2016.
SKILLS AND QUALIFICATIONS |
Business Leader. Executive leadership and management experience, including Mr. Cordani's current role as President and Chief Executive Officer of Cigna. His prior role as Chief Operating Officer also encompassed broad responsibility for Cigna's global business and corporate functions.
Finance. Served as Business Financial Officer for Cigna's healthcare division and in senior roles in corporate accounting and planning. Formerly a CPA with public accounting experience at Coopers & Lybrand.
Marketing and Consumer Insights. As Chief Executive Officer, leads Cigna's Go Deep, Go Global, Go Individual strategy, to deliver value in more than 85 million customer relationships around the world.
Information Technology. Manages Cigna's information technology investments in support of business and strategic objectives.
Healthcare and Delivery Systems. President and Chief Executive Officer of Cigna Corporation, a global health service company. Prior President of Cigna HealthCare business segment. Long tenure with Cigna provides Mr. Cordani with unique perspective of the evolution of the healthcare service sector and the innovation of health delivery models.
Regulated Industry/Public Policy. Active in public policy related to the highly regulated healthcare industry and other global business markets.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 17
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Eric J. Foss, Chairman, President and Chief Executive Officer of ARAMARK Corporation |
| | | | |
| Mr. Foss, 56, has served on Cigna's Board since 2011. He currently serves on the Corporate Governance and People Resources Committee. | | ||
| | | | |
Mr. Foss has been President, Chief Executive Officer and a Director of ARAMARK Corporation, a publicly traded provider of food services, facilities management and uniform services, since May 2012. He has also served as Chairman of the Board since February 2015. He served as Chief Executive Officer of Pepsi Beverages Company, a beverage manufacturer, seller and distributor and a division of PepsiCo, Inc., from 2010 until December 2011. He served with The Pepsi Bottling Group, Inc. as its Chairman and Chief Executive Officer from 2008 until 2010; President and Chief Executive Officer from 2006 until 2008; and Chief Operating Officer from 2005 until 2006. Mr. Foss has served on the Board of UDR, Inc., a publicly traded real estate investment trust, since 2003. His current term as a Director of Cigna began in 2014 and expires in 2017.
SKILLS AND QUALIFICATIONS |
Business Leader. Extensive leadership experience as the Chairman and CEO of ARAMARK Corporation, combined with his 30-year career at Pepsi Beverages Company and The Pepsi Bottling Group, including his role as Chairman and CEO.
Finance. As Chairman and CEO of ARAMARK and as Chief Executive Officer of Pepsi Beverages Company and The Pepsi Bottling Group, oversight of financial operations, financial reporting, merger and acquisition activities and corporate restructurings. He led ARAMARK's initial public offering in 2013 and was instrumental in The Pepsi Bottling Group's initial public offering and oversaw its acquisition by PepsiCo.
Marketing and Consumer Insights. Service as CEO of Pepsi Beverages Company and The Pepsi Bottling Group provided experience as executive officer of a consumer oriented company.
International/Global. Responsibilities at ARAMARK, Pepsi Beverages Company and The Pepsi Bottling Group included international business leadership, managing the challenges of operating a global business, and strategic planning. At ARAMARK, has oversight of operations in 20 countries, and throughout his tenure at Pepsi Beverage Company and The Pepsi Bottling Group, had responsibilities for global operations including international assignments.
18
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Michelle D. Gass, Chief Customer Officer of Kohl's Corporation |
| | | | |
| Ms. Gass, 46, has served on Cigna's Board since 2014. She currently serves on the Audit and Corporate Governance Committees. | | ||
| | | | |
Ms. Gass has served as Chief Customer Officer of Kohl's Corporation, a publicly traded retailer, since 2013. Prior to this, Ms. Gass held various roles with Starbucks Coffee Company, a publicly traded manufacturer and retailer, for more than 16 years, including President, Starbucks Coffee, EMEA, from 2011 to 2013; President of the Seattle's Best Coffee Unit and Interim President of the Global Consumer Products Division from 2009 to 2011; Executive Vice President, Global Marketing and Category and Chief Global Strategist from 2008 to 2009. Ms. Gass also served as a director of Ann, Inc., a publicly traded retailer, from 1998 to 2013. Her current term as a Director of Cigna began in 2014 and expires in 2017.
SKILLS AND QUALIFICATIONS |
Business Leader. As the Chief Customer Officer of Kohl's Corporation, and having held roles of increasing responsibility over her 15-year career at Starbucks Coffee Company.
Marketing and Consumer Insights. Responsible for Kohl's overall customer engagement strategy, including the company's digital, marketing, public relations, and social responsibility efforts, as well as the high growth omni-channel business. During her
Starbucks tenure, held a variety of leadership roles across marketing, global strategy and category management, playing a key role in the company's overall strategic blueprint.
International/Global. As President, Starbucks EMEA (Europe, Middle East, Russia and Africa), oversaw and grew the company's 1,900 owned and licensed store operations across the region and included international assignments.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 19
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Isaiah Harris, Jr., Former President and Chief Executive Officer of AT&T Advertising & Publishing East |
| | | | |
| Mr. Harris, 62, has served on Cigna's Board since 2005. He has served as Chairman of the Board since 2009 and currently chairs the Executive Committee. | | ||
| | | | |
Mr. Harris has served as Chairman of the Board since December 2009 and served as Vice-Chairman of the Board from July 2009 through December 2009. Mr. Harris served as President and Chief Executive Officer of AT&T Advertising & Publishing East (formerly BellSouth Advertising & Publishing Group), a communications services company, from 2005 until his retirement in 2007; as President, BellSouth Enterprises, Inc. from 2004 until 2005 and as President, Consumer Services, BellSouth Corporation from 2000 until 2004. Mr. Harris has served as an Independent Trustee of Wells Fargo Advantage Funds, a provider of mutual funds, since 2008 and served as a Director of Deluxe Corporation, a provider of customized products and services including financial services and direct checks, from 2004 until 2011. Mr. Harris was nominated as NYSE 2014 Chairman of the Year and was recognized by the Outstanding Directors Exchange as a 2010 Outstanding Director. His current term as a Director of Cigna began in 2013 and expires in 2016.
SKILLS AND QUALIFICATIONS |
Business Leader. In his executive business leadership roles, including as CEO of AT&T Advertising and Publishing, managed large organizations, developed and executed business strategies and led transformational change initiatives in both domestic and international operations.
Finance. Extensive business experience that includes 19 years of corporate finance and operational experience in multi-national organizations, including as Vice President of Finance, BellSouth Corporation, preceded by 13 years as a CPA with KPMG LLP. Through service on the Deluxe board of directors and as a
trustee of Wells Fargo Advantage Funds, developed insight into financial services-related issues.
Marketing and Consumer Insights. Throughout his career with AT&T Advertising & Publishing, and particularly as President, Consumer Services, BellSouth Corporation (2000 to 2004), focused on marketing communication services to end-user consumers.
Regulated Industry/Public Policy. Throughout his career at AT&T Advertising & Publishing, navigated a heavily regulated and dynamic legal environment.
20
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Jane E. Henney, M.D., Former Senior Vice President, Provost and Professor of Medicine, University of Cincinnati College of Medicine |
| | | | |
| Dr. Henney, 67, has served on Cigna's Board since 2004. She currently chairs the Corporate Governance Committee and serves on the Executive and People Resources Committees. | | ||
| | | | |
Dr. Henney served as a Professor of Medicine at the University of Cincinnati College of Medicine, an educational institution, from 2008 until 2012. She served as Senior Vice President and Provost, Health Affairs at the University of Cincinnati Academic Health Center from 2003 until 2008. Appointed by Bill Clinton, Dr. Henney served as the first female U.S. Commissioner of Food and Drugs from 1998 to 2001. Dr. Henney was appointed to the position of Home Secretary of the Institute of Medicine, a division of The National Academies of Sciences designed to advise the nation on health issues, in April 2014. She has been a Director of AmerisourceBergen Corporation, a publicly traded bio-pharmaceutical company, since 2002 and served as a director of Cubist Pharmaceuticals, Inc., a publicly traded pharmaceutical and biologics company, from 2012 until January 2015. She also served as a Director of AstraZeneca PLC from 2001 until 2011. She received recognition from the National Association of Corporate Directors as an NACD Directorship 100 "Class of 2011" and "Class of 2012" member. Dr. Henney also is an NACD Board Leadership Fellow. Her current term as a Director of Cigna began in 2013 and expires in 2016.
SKILLS AND QUALIFICATIONS |
Healthcare and Delivery Systems. Medical Doctor, Home Secretary of the Institute of Medicine, Commissioner of Food and Drugs, Executive of Academic Health Center roles provide direct experience regarding emerging health care issues and complex health delivery systems.
Regulated Industry/Public Policy. As former Commissioner of Food and Drugs and Home Secretary of the Institute of Medicine provides extensive insight into highly regulated health industry in the U.S and abroad.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 21
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Roman Martinez IV, Private Investor |
| | | | |
| Mr. Martinez, 67, has served on Cigna's Board since 2005. He currently serves on the Audit and Finance Committees. | | ||
| | | | |
Mr. Martinez has been a private investor since 2003. In 2003, he retired as Managing Director of Lehman Brothers, an investment banking firm, following a 31-year career with the firm. He served as a director of Alliant Techsystems Inc., a publicly traded aerospace, defense and commercial products company, from 2004 until February 2015, when Alliant Techsystems, Inc. merged with Orbital Sciences, Inc. to create Orbital ATK, Inc. and simultaneously spun-off its commercial products company. Mr. Martinez has served as a director of Orbital ATK, Inc. since February 2015. Mr. Martinez has served on the Board of Trustees of New York Presbyterian Hospital since 1996. His current term as a Director of Cigna began in 2014 and expires in 2017.
SKILLS AND QUALIFICATIONS |
Finance. Over ten years of experience as a private investor, and serving on the Investment Committees of several non-profit organizations and on the Investment Advisory Council of the State of Florida, which provides independent oversight of the Florida Retirement System funds and other state funds, which aggregated in excess of $150 billion. Extensive experience in investment banking through his 31-year tenure with Lehman Brothers where he was involved in a broad spectrum of U.S. and international investment banking activities covering
financial, mergers and acquisitions, and restructuring advisory assignments as well as financing transactions for governments and corporations.
Healthcare and Delivery Systems. Through over 15 years serving on the Board of Trustees of New York Presbyterian Hospital, developed insights into the issues facing health care systems in a rapidly changing environment, including the provision of care management and delivery systems.
22
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Donna F. Zarcone, President and Chief Executive Officer of The Economic Club of Chicago |
| | | | |
| Ms. Zarcone, 57, has served on Cigna's Board since 2005. She currently chairs the Audit Committee and serves on the Executive and Finance Committees. | | ||
| | | | |
Ms. Zarcone has been the President and Chief Executive Officer of The Economic Club of Chicago, a civic and business leadership organization, since February 2012. She served as Interim President of The Economic Club of Chicago from October 2011 until February 2012 and as President and Chief Executive Officer of D. F. Zarcone & Associates LLC, a strategic advisory firm, from 2007 until February 2012. Ms. Zarcone served as the President and Chief Operating Officer of Harley-Davidson Financial Services, Inc., a provider of wholesale and retail financing, insurance and credit card programs and a wholly owned subsidiary of Harley-Davidson, Inc., from 1998 until 2006. She has been a Director of CDW Corporation, a publicly traded provider of technology products and services, since 2011. She also served as a Director of The Jones Group, Inc., a publicly traded designer, marketer and wholesaler of branded clothing, from 2007 to 2012 and Chairman of the Board of Eaglemark Savings Bank, a financial services provider, from 2002 to 2006. She received recognition from the National Association of Corporate Directors as an NACD Directorship 100 "Class of 2012" member. Her current term as a Director of Cigna began in 2013 and expires in 2016.
SKILLS AND QUALIFICATIONS |
Finance. As an executive at Harley-Davidson Financial Services and as the Chairman of the Board of Eaglemark Savings Bank, an FDIC-regulated entity, oversaw end-user consumer financial services matters. She is a certified public accountant. As President and CEO of The Economic Club of Chicago, monitors social and economic issues facing the U.S. and global markets.
Marketing and Consumer Insights. As President of Harley-Davidson Financial Services, oversaw direct marketing initiatives to end-user consumers for a portfolio of financial products. As head of Enthusiast Services at Harley-Davidson, oversaw brand loyalty initiatives. As a director of The Jones Group, focused on end-user consumer-related issues.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 23
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
William D. Zollars, Former Chairman, President and Chief Executive Officer of YRC Worldwide, Inc. |
| | | | |
| Mr. Zollars, 67, has served on Cigna's Board since 2005. He currently chairs the People Resources Committee and serves on the Executive and Corporate Governance Committees. | | ||
| | | | |
Mr. Zollars served from 1999 to 2011 as Chairman, President and Chief Executive Officer of YRC Worldwide, Inc., a holding company whose subsidiaries provide regional, national and international transportation and related services. Prior to that, Mr. Zollars was President of Yellow Transportation, Inc., from September 1996 through November 1999. From 1994 to 1996, he was Senior Vice President of Ryder Integrated Logistics. He also held various executive positions with Eastman Kodak. Mr. Zollars served as Director of ProLogis Trust, a real estate investment trust, from 2004 through 2010 and rejoined the Board of ProLogis in 2011. He has served as a Director of Cerner Corporation, a publicly traded supplier of health care information technology, since 2005. His current term as a Director of Cigna began in 2014 and expires in 2017.
SKILLS AND QUALIFICATIONS |
Business Leader. Chairman, President and Chief Executive Officer of YRC Worldwide and various executive leadership positions with Yellow Transportation, Ryder Integrated Logistics and Eastman Kodak provided extensive senior leadership experience.
Finance. As Chairman, President and CEO of YRC Worldwide, had oversight of financial operations, merger and acquisition activities and corporate restructurings and led YRC's comprehensive recovery plan to reduce cost
structure and improve operating results, cash flow from operations, liquidity and financial condition.
International/Global. As President and CEO of YRC, oversaw global operations and strategic planning and, throughout his YRC tenure, included international assignments.
Healthcare and Delivery Systems. As a director of Cerner, focuses issues facing the healthcare industry, particularly health information technology.
24
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
GOVERNANCE POLICIES AND PRACTICES
Cigna is committed to ensuring strong corporate governance practices on behalf of our shareholders. We believe that strong corporate governance provides the foundation for financial integrity, shareholder confidence and attractive performance. Cigna's Board Practices, together with the charters of the Audit, Corporate Governance, Finance, People Resources and Executive Committees, establishes a framework of policies and practices for our effective governance. Our Board Practices, which are available at www.cigna.com/about-us/corporate-governance/board-practices, address Board structure and leadership, director qualifications, director independence, committee structure and roles, people development and succession planning. The Board, the Corporate Governance Committee and the other committees regularly review their governance policies and practices and developments in corporate governance and update these documents as they deem appropriate for Cigna.
The following describes some of our most significant governance practices by area, which are discussed in greater detail in this section and the Compensation Discussion & Analysis (CD&A) beginning on page 46.
OVERSIGHT OF EXECUTIVE COMPENSATION
ALIGNMENT WITH SHAREHOLDER INTERESTS High percentage of performance-based executive pay Majority of director compensation delivered in Cigna common stock Meaningful stock ownership guidelines for directors and executive officers Restrictions on hedging and pledging of Cigna common stock Annual public disclosure of political
contributions and lobbying activity |
The Questions and Answers section beginning on page 98 includes instructions for how to obtain copies of Cigna's corporate governance policies and how to communicate with the Board of Directors.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 25
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
ROLE OF THE BOARD AND LEADERSHIP STRUCTURE
The Board's primary role is the oversight of the management of Cigna's business affairs and assets in accordance with the Board's fiduciary duties to shareholders under Delaware law. To fulfill its responsibilities to our shareholders, Cigna's Board, both directly and through its committees, regularly engages with management, ensures management accountability and reviews the most critical issues that face Cigna. Among other things, the Board reviews the Company's strategy and mission, its execution on financial and strategic plans and succession planning. The Board also oversees risk management. All directors play an active role in overseeing the Company's business strategy at the Board and committee levels. The Board is committed to meeting the dynamic needs of the Company and focusing on the interests of its shareholders and, as a result, regularly evaluates and adapts its composition, role and relationship with management.
Independent Board Members |
Cigna believes in the importance of a board comprised largely of independent, non-employee directors. Currently, the Board has determined that all Cigna directors, other than the Company's Chief Executive Officer (CEO), are independent under New York Stock Exchange (NYSE) listing standards and SEC rules. Similarly, at the committee level, all committee members are independent and the members of the Audit Committee and the People Resources Committee meet the NYSE's heightened independence requirements for service on those committees.
Independent Chairman of the Board |
We currently separate the roles of the Chairman of the Board and CEO, and have elected Isaiah Harris, Jr. to serve as our independent Chairman. We believe that having an independent Chairman assists in ensuring independent oversight of the Company and the management team. The Board regularly assesses the appropriateness of this leadership structure and has concluded that this structure is appropriate for Cigna at this time. The Board elects the Chairman to a three-year term, expiring at the annual meeting occurring at the end of the third year. Mr. Harris' current term as Chairman will expire in April 2015, and in February 2015, the Board re-elected Mr. Harris to another three-year term. The full Board evaluates the Chairman's performance on an annual basis as part of the annual Board evaluation, which was led by an independent third party in 2014.
The following table describes the key responsibilities of the Chairman of the Board.
CHAIRMAN RESPONSIBILITIES | ||
Serve as principal representative of the Board Preside over Board and shareholder meetings Facilitate discussion among independent directors on key issues Advise the CEO on issues of concern for the Board Develop schedule and agenda of Board meetings, in consultation with the CEO and other directors |
Act as liaison between Board and management Lead the Board in CEO succession planning Engage in the director recruitment process Represent the Company in interactions with external stakeholders, at the discretion of the Board |
26
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Cigna employs a number of other practices directed to ensure the highest level of corporate governance oversight on behalf of its shareholders. The following tables describe some of these practices in more detail.
|
PRACTICES DIRECTED TO INDIVIDUAL CIGNA DIRECTORS |
|
||||
|
Limits on Public Company |
To ensure each director is able to devote sufficient time and attention to his or her responsibilities as a board member, the Board has established the following limits on outside directorships: Each director who also is a chief executive officer of a public company may not serve on more than one other public company board in addition to Cigna's Board and the board of his or her employer (for a total of three public company directorships); and |
||||
|
Each director who is not a chief executive officer of a public company may serve on no more than four boards of other public companies (for a total of five such directorships). |
|||||
|
All of our directors are in compliance with these limits on outside directorships. |
|||||
| | | | | | |
|
Change in Director's Principal |
If a director changes his or her principal employment position, that director is required to tender his or her resignation to the Corporate Governance Committee. The committee will then recommend to the Board whether to accept or decline the resignation. |
||||
| | | | | | |
|
Mandatory Retirement Age |
A director is required to retire no later than the annual meeting of shareholders coinciding with or following his or her 72nd birthday. |
||||
| | | | | | |
|
Continuing Education for Directors |
The Board is regularly updated on Cigna's businesses, strategies, customers, operations and employee matters, as well as external trends and issues that affect the Company. Directors also are encouraged to attend continuing education courses relevant to their service on Cigna's Board. The Corporate Governance Committee oversees the continuing education practices, and the Company is kept apprised of director participation. Cigna reimburses directors for expenses they incur in connection with continuing education courses. |
||||
| | | | | | |
|
Attendance at Annual Meeting of |
The Board encourages directors to attend the annual meeting of shareholders. In 2014, all directors attended the annual meeting. All directors are expected to attend the annual meeting in 2015. |
||||
| | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 27
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
|
PRACTICES DIRECTED TO CIGNA BOARD PROCESSES |
|
||||
|
Board Executive Sessions of Independent Directors |
As part of all regularly scheduled Board meetings, the Chairman presides over all executive sessions of the Board. At each meeting held in 2014, the independent members of the Board met in executive session. Each Board committee also met in executive session on a regular basis in connection with their respective meetings. |
||||
| | | | | | |
|
Director Access to Management |
Each committee is assigned a member of senior management to act as a staff officer. The staff officers are invited to attend the committee meetings and Board meetings. Each committee chair works with the staff officer assigned to his or her committee to set and develop meeting agenda and materials and communicates frequently with staff officers and members of management between scheduled Board meetings with respect to committee issues. |
||||
| | | | | | |
|
Independent Advisors |
The Board and its committees are able to access and retain independent advisors as and to the extent they deem necessary or appropriate. |
||||
| | | | | | |
|
CEO Succession Planning |
At the direction of the Chairman, the Board oversees CEO succession planning. With the assistance of the People Resources Committee, the Board reviews and approves regular and emergency succession plans and, as part of those plans, develops and evaluates potential candidates who have the skills and experience that the Board believes is necessary for the CEO position. |
||||
| | | | | | |
|
People Development and Other |
The People Resources Committee also is responsible for overseeing the Company's policies and processes for people development in general, including the succession plan for all other executive officers. In fulfilling that responsibility, the People Resources Committee considers an annual review of executive officers and key senior management presented by the CEO, including a discussion of those employees who are considered to be potential successors to executive and senior level positions with regard to their readiness and development opportunities. This assessment is presented to the full Board at the People Resources Committee's direction. |
||||
| | | | | | |
|
Annual Board Evaluation |
Each year, the Corporate Governance Committee oversees the evaluation of the Board and its committees, as well as a review of each individual director's performance (including the Chairman's) against the established responsibilities of Cigna Board members. Each committee also is responsible for conducting a self-assessment to identify potential areas of improvement. On an ongoing basis, directors offer suggestions and recommendations intended to further improve Board performance. In 2014, the Board engaged an independent third party advisor to conduct an in-depth evaluation of the Board and each of its committees. The advisor made a report of its findings to the Board and its committees in December 2014. |
||||
| | | | | | |
28
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
|
PRACTICES DIRECTED TO CIGNA SHAREHOLDERS |
|
||||
|
Alignment of Director Compensation |
Cigna delivers the majority of compensation to non-employee directors in the form of Cigna common stock and requires directors to meet a stock ownership guideline of at least $500,000 (or over five times the annual cash retainer). For more information on non-employee director compensation, see page 35. |
||||
| | | | | | |
|
Majority Voting Standard |
Cigna has adopted a majority voting standard for the election of directors in uncontested elections that requires a director to tender his or her resignation upon that director's failure to be elected by shareholders. See Process for Director Elections on page 11. |
||||
| | | | | | |
|
No Shareholder Rights Plan |
Cigna does not have a shareholder rights plan and, at this time, the Board has no intention of adopting such a plan. |
||||
| | | | | | |
|
Annual Political Contribution and Lobbying Activity Report |
Cigna supports the goals of transparency and accountability with regard to corporate political expenditures. In 2011, Cigna published its
first annual political contributions and lobbying activity report that provided information on its political contributions, lobbying activities, trade association affiliations and related matters. Since then, we have significantly enhanced this
report to provide greater clarity on our overall lobbying framework, including the areas in which we focus our advocacy efforts and why we believe active engagement in the public policy arena is important to our mission, business and customers. We
also provide specific details regarding: (1) the direct political contributions that Cigna makes at a corporate level; (2) contributions that Cigna makes through the Cigna Political Action Committee; and (3) the total amount of dues
paid to any industry trade association to which Cigna pays $50,000 or more in annual dues, as well as the portion of any such dues that they inform us are allocable to any non-deductible lobbying expenses. |
||||
| | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 29
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
In 2014, the Board held seven meetings and the committees of the Board held a total of 27 meetings. Overall director attendance at Board and committee meetings was approximately 96.5%. Each director attended 75% or more of the aggregate of all meetings of the Board and committees on which he or she served during 2014. In addition to formal Board meetings, the Board engages with management throughout the year on critical matters and topics.
The Board has the following committees: Executive, Corporate Governance, Finance, People Resources and Audit. In its discretion and subject to Delaware law, the Board and each committee may delegate all or a portion of its authority to subcommittees of one or more of its members. Additional information can be found in the committee charters adopted by the Board and available on Cigna's website at www.cigna.com/aboutus/board-committees. Each committee member meets the independence standards required for the committee on which he or she serves.
EXECUTIVE COMMITTEE
CORPORATE GOVERNANCE COMMITTEE
FINANCE COMMITTEE
30
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
PEOPLE RESOURCES COMMITTEE
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 31
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
The directors serve on the following committees.
|
Executive |
|
Corporate Governance |
|
Finance |
|
People Resources |
|
Audit* |
|
||||||||||||||
David M. Cordani | | |||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| Eric J. Foss | | | | | | | | | | | | ||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
Michelle D. Gass | | | ||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| Isaiah Harris, Jr. | | Chair | | | | | | ||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
Jane E. Henney, M.D | | Chair | | |||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| Roman Martinez IV | | | | | | | # | | |||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
John M. Partridge | | Chair | | |||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| James E. Rogers | | | | | | | # | | |||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
Eric C. Wiseman | | | ||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| Donna F. Zarcone | | | | | | | | Chair # | | ||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
William D. Zollars | | | Chair | |||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| Meetings in 2014 | | 0 | | 5 | | 5 | | 8 | | 9 | | ||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
BOARD OVERSIGHT OF RISK AND ENTERPRISE RISK MANAGEMENT
The Board of Directors has the ultimate responsibility for risk oversight under the Company's risk management framework. The Board executes its duty both directly and through its Audit, Corporate Governance, Finance and People Resources Committees. The Audit Committee oversees Cigna's enterprise risk management (ERM) framework. ERM is a Company-wide initiative that involves the Board, Cigna's management, Cigna's Chief Risk Officer and General Auditor (CRO) and internal audit function in an integrated effort to (1) identify, assess, prioritize and monitor a broad range of risks and (2) formulate and execute plans to monitor and, to the extent possible, mitigate the effect of those risks. The CRO meets with the Audit Committee regularly during its executive sessions and makes reports to the Board at least annually.
Cigna has implemented practices so that the Board and its committees are regularly briefed on issues related to the Company's risk profile. These reports are designed to provide visibility to the Board about the identification, assessment and management of critical risks and management's risk mitigation strategies. These areas of focus include strategic, operational, financial and reporting, succession and compensation, compliance, reputational, governance and other risks.
32
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
The Board, including its committees, oversees risks associated with their respective areas of responsibility, as summarized below. Each committee meets in executive session and with key management personnel and representatives of outside advisors as necessary.
Board/Committee |
Primary Areas of Risk Oversight |
|
||||
Full Board | Strategic, financial and execution risks and exposures associated with Cigna's business strategy, including impact of changes to laws and regulations, significant litigation and regulatory exposures, and other current matters that may present material risk to financial performance, operations, infrastructure, plans, prospects or reputation, acquisitions and divestitures. | |||||
Audit Committee |
In addition to overseeing Cigna's ERM framework, oversees risks related to the Company's financial statements, the financial reporting process, accounting, cyber-security and certain legal and compliance matters. The Audit Committee also oversees the internal audit function and the Company's ethics and compliance program. |
|
||||
Corporate Governance Committee |
Oversees risks and exposures associated with director succession planning, corporate governance and overall Board effectiveness. Also oversees the Company's risks related to political and charitable contributions. In exercising this oversight, the Corporate Governance Committee reviews and discusses financial contributions to such organizations. |
|||||
Finance Committee |
Oversees the Company's deployment of capital and technology and investment-related initiatives. In exercising this oversight, the Finance Committee regularly reviews and discusses the technology, financial market and capital management risks that are monitored through the Company's ERM process. |
|
||||
People Resources Committee |
Oversees compensation related-risks and management succession planning. For additional information regarding the People Resources Committee's role in evaluating the impact of risk on executive compensation, see page 68 of the CD&A. |
|||||
| | | | | | |
The current Board includes 10 non-employee directors. On an annual basis, the Board, through its Corporate Governance Committee, reviews relevant relationships between directors, their immediate family members and the Company, consistent with Cigna's independence standards. Cigna's standards, which are detailed in Cigna's Board Practices available at www.cigna.com/about-us/corporate-governance, conform to the independence requirements set forth in the NYSE's listing standards.
To be independent under NYSE and Cigna standards, the Board must affirmatively determine that a director has no material relationships with the Company directly or as an officer, shareholder or partner of an organization that has a relationship with the Company. In making its assessment, the Board considers all relevant facts and circumstances, including whether transactions with such organizations are in the ordinary course of Cigna's business and/or the amount of such transactions (in aggregate or as a percentage of the organization's revenues or assets). The Board also considers that the Company may sell products and services to, and/or purchase products and services from, organizations affiliated with our directors and may hold investments (generally, debt securities) in organizations affiliated with our directors.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 33
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Based on its review of director relationships, the Board has affirmatively determined that there are no material relationships between the non-employee directors and the Company and all non-employee directors (Dr. Henney, Ms. Gass, Ms. Zarcone and Messrs. Foss, Harris, Martinez, Partridge, Rogers, Wiseman and Zollars) are independent as defined in both the NYSE listing standards (including those applicable to certain board committees) and Cigna's director independence standards.
Cigna is committed to integrity, legal compliance and ethical conduct. All directors and employees, including our executive officers, must comply with the Company's Code of Ethics. The Code of Ethics and Cigna's related policies and procedures address major areas of professional conduct, including, among others, conflicts of interest, protection of private, sensitive or confidential information, employment practices, insider trading and adherence to laws and regulations affecting the conduct of Cigna's business.
The Code of Ethics requires disclosure to the Company of any existing or proposed relationship, financial interest or business transaction that could be, or might appear to be, a conflict of interest. Directors and officers cannot participate in a personal transaction with Cigna without first notifying and obtaining the approval of Cigna's General Counsel.
Transactions with Related Persons |
Cigna has not adopted a written policy concerning review, approval or ratification of related person transactions. Cigna compiles information about transactions between Cigna and Cigna's directors, director nominees and executive officers and any immediate family members and affiliated entities identified by directors, director nominees and executive officers as having any form of relationship with Cigna. Cigna's Office of the Corporate Secretary analyzes the nature of any transaction to determine whether the transaction may require disclosure under SEC rules as a related person transaction. On an annual basis, the Corporate Governance Committee reviews the analysis prepared by the Company, and presents its assessment to the full Board of Directors.
Based on this review, there are no related person transactions requiring disclosure under SEC rules.
Compensation Committee Interlocks and Insider Participation |
The People Resources Committee comprises the five independent directors listed above on page 32. There are no compensation committee interlocks.
34
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
NON-EMPLOYEE DIRECTOR COMPENSATION
The Corporate Governance Committee reviews and makes recommendations to the Board about the compensation paid to non-employee directors for service on the Cigna Board of Directors. A director who also is an employee of the Company does not receive payment for services as a director. The CEO is the only employee who currently serves as a director.
The Board believes that the current director compensation program:
The Corporate Governance Committee's charter provides that it will periodically review director compensation and assist the Board in the administration of director compensation plans. The Board approves the amount and form of director compensation. The Corporate Governance Committee may from time to time engage a compensation consultant to assist in its review of director compensation. Under our policies, this compensation consultant must be independent from the Company. The independence requirements for a director compensation consultant engaged by the Corporate Governance Committee are identical to those required by the People Resources Committee for its executive compensation consultant, as described on page 69.
The Corporate Governance Committee reviews Cigna's non-employee director compensation program on a periodic basis. In October 2011, the Board, upon recommendation from the Corporate Governance Committee, approved the current director compensation program, effective as of January 2012. In 2014, the Board and the Corporate Governance Committee reviewed the director compensation program and did not make any changes.
The following chart summarizes the retainer compensation provided to directors for their service on Cigna's board. Payments are made in equal, quarterly installments.
|
Retainer type |
|
Annual amount | Method of payment | | ||||
|
Board |
$ | 275,000 | Cigna common stock ($180,000) Cash ($95,000) |
|||||
|
Committee chair |
$ | 15,000 | Cash | | ||||
|
Committee member |
$ | 10,000 | Cash | |||||
| | | | | | | | | |
There is no retainer for service on the Executive Committee. In addition to the Board retainer, the Chairman of the Board receives $225,000 in cash for his service as Chairman.
Deferral of Payments |
Under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation (Deferral Plan), directors may elect to defer the payment of the cash and/or common stock portion of their annual retainers. Deferred common stock compensation is credited to a director's deferred compensation account as a number of shares
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 35
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
of hypothetical common stock and ultimately paid in shares. Deferred cash compensation is ultimately paid in cash, and directors have a choice of hypothetical investment funds whose rates of return are credited to that account. These funds include a Cigna stock fund and several other funds selected from those offered to all Cigna employees under the Cigna 401(k) Plan. Directors may elect to receive payments under the Deferral Plan in a lump sum or installments. Lump sum payments are made, or installments begin, in January of the year following a director's separation from service or a specified year while still in service.
Stock Ownership Guideline |
Cigna requires directors to maintain a stock ownership level of at least $500,000 (or over five times the annual Board cash retainer) in value of Cigna common stock. Common stock, deferred common stock, restricted stock units and hypothetical shares of Cigna common stock held by a director count toward the stock ownership guidelines for directors whose service started before February 2014. Directors whose service started after February 2014 may count common stock and deferred common stock for compliance. As of December 31, 2014, all of the directors, other than Ms. Gass, met the stock ownership guideline. Ms. Gass has until April 2019 (five years from her election to the Board) to satisfy her stock ownership obligations.
Financial Planning and Matching Charitable Gift Programs |
Directors may participate in the same financial planning and tax preparation program available to Cigna executive officers. Under this program, Cigna will make direct payments or reimburse directors for financial planning services that are provided by firms designated by Cigna and for tax preparation services in the amount of up to $6,500 annually. Each director whose service started before 2006 and has at least nine years of board service upon separation from service also is eligible for direct payments or reimbursement in the amount of up to $5,000 for financial planning and tax preparation services during the one-year period following separation.
Directors also may participate in the matching charitable gift program available to Cigna employees, under which Cigna will make a matching charitable gift of up to $5,000 annually. In addition, upon a director's retirement, in recognition of the retiring director's service, the Board may make a donation in the amount of $10,000 to a charitable organization of the director's choice.
Insurance Coverage |
Cigna offers to each director, at no cost to the director, group term life insurance coverage equal to the annual Board retainer ($275,000 during 2014), and business travel accident insurance coverage equal to three times the annual Board retainer ($825,000 during 2014).
Directors also may purchase or participate in, by paying premiums on an after-tax basis, additional life insurance, medical care, long-term care, property/casualty personal lines, and various other insurance programs available on a broad basis to Cigna employees. Directors also may elect to purchase worldwide emergency assistance coverage. This program, which provides international emergency medical, personal, travel and security assistance, also is available to Cigna executive officers and certain other Cigna employees who frequently travel abroad for business.
All retired directors have the opportunity to continue other life insurance, long-term care insurance and property/casualty personal lines of insurance pursuant to the terms of the applicable Cigna policies, at the director's own expense.
36
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
In addition, Cigna provides each retired director whose service started before 2006 and who has at least nine years of Board service upon separation from service with $10,000 of group term life insurance coverage, with premiums paid by Cigna. These directors may also participate for two years following separation from service in the medical care programs currently offered by Cigna to retired employees, with premiums paid by the director on an after-tax basis.
DIRECTOR COMPENSATION TABLE FOR 2014
The table below includes information about the compensation paid to non-employee directors in 2014. Mr. Cordani, the only Company employee on the Board of Directors, does not receive any director compensation for his Board service.
Name (a) |
|
Fees Earned or Paid in Cash ($) (b) |
|
Stock Awards ($) (c) |
|
All Other Compensation ($) (d) |
|
Total Compensation ($) (e) |
| |||||||
Eric J. Foss | 115,000 | 180,000 | 338 | 295,338 | ||||||||||||
| Michelle D. Gass(1) | | 86,250 | | 135,000 | | 226 | | 221,476 | | ||||||
Isaiah Harris, Jr. | 320,000 | 180,000 | 892 | 500,892 | ||||||||||||
| Jane E. Henney, M.D. | | 120,000 | | 180,000 | | 6,131 | | 306,131 | | ||||||
Roman Martinez IV | 115,000 | 180,000 | 1,170 | 296,170 | ||||||||||||
| John M. Partridge | | 120,000 | | 180,000 | | 5,338 | | 305,338 | | ||||||
James E. Rogers | 115,000 | 180,000 | 617 | 295,617 | ||||||||||||
| Joseph P. Sullivan(2) | | 115,000 | | 180,000 | | 434 | | 295,434 | | ||||||
Eric C. Wiseman | 115,000 | 180,000 | 621 | 295,621 | ||||||||||||
| Donna F. Zarcone | | 120,000 | | 180,000 | | 6,113 | | 306,113 | | ||||||
William D. Zollars | 120,000 | 180,000 | 990 | 300,990 | ||||||||||||
| | | | | | | | | | | | | | | | |
Fees Earned or Paid in Cash (Column (b))
Stock Awards (Column (c))
Column (c) lists the aggregate grant date fair value of Cigna common stock awarded to directors as part of their Board retainer, computed in accordance with FASB Accounting Standards Codification (ASC) Topic 718, applying the same model and assumptions that Cigna applies for financial statement
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 37
|
CORPORATE GOVERNANCE MATTERS (CONTINUED)
reporting purposes as described in Note 20 to Cigna's consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 (disregarding any estimates for forfeitures). See Director Ownership below for amounts and a description of equity-based awards outstanding as of December 31, 2014.
All Other Compensation (Column (d))
Column (d) includes:
Column (d) does not include the value of premiums, if any, paid by the directors for additional life insurance, medical care programs, long-term care, property/casualty personal lines, and various other insurance programs that also are available on a broad basis to Cigna employees.
The table shows Cigna securities held by each director as of December 31, 2014. The value of these securities was calculated using $102.91, which was Cigna's closing stock price on December 31, 2014.
|
Name |
|
Common Stock (a) |
|
Deferred Common Stock (b) |
|
Restricted Stock Units (c) |
|
Hypothetical Shares of Common Stock (d) |
|
Total Ownership (e) |
|
Total Ownership Value (f) |
| ||||||||
|
Eric J. Foss |
9,677 | | | | 9,677 | $ 995,860 | |||||||||||||||
|
Michelle D. Gass |
| 1,413 | | | | | | | | 1,413 | | $ 145,412 | | ||||||||
|
Isaiah Harris, Jr. |
| | 13,500 | 23,236 | 36,736 | $3,780,502 | |||||||||||||||
|
Jane E. Henney, M.D. |
| 500 | | | | 13,500 | | 19,024 | | 33,024 | | $3,398,500 | | ||||||||
|
Roman Martinez IV |
9,496 | 19,044 | 13,500 | 15,410 | 57,450 | $5,912,180 | |||||||||||||||
|
John M. Partridge |
| 20,711 | | | | | | | | 20,711 | | $2,131,369 | | ||||||||
|
James E. Rogers |
| 33,784 | | 9,202 | 42,986 | $4,423,689 | |||||||||||||||
|
Joseph P. Sullivan |
| 11,828 | | 2,389 | | | | | | 14,217 | | $1,463,071 | | ||||||||
|
Eric C. Wiseman |
4,200 | 8,381 | | 1,263 | 13,844 | $1,424,686 | |||||||||||||||
|
Donna F. Zarcone |
| 5,971 | | 4,494 | | 13,500 | | 2,795 | | 26,760 | | $2,753,872 | | ||||||||
|
William D. Zollars |
| | 13,500 | 9,778 | 23,278 | $2,395,539 | |||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | |
Deferred Common Stock (Column (b))
Column (b) includes the equity portion of the 2014 and any previous year's Board retainer granted in Cigna common stock or deferred stock units that have been deferred under the Deferral Plan.
38
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
CORPORATE GOVERNANCE MATTERS (CONTINUED)
Restricted Stock Units (Column (c))
Column (c) includes restricted stock units that were issued in April 2014 upon the cancellation and exchange of 13,500 restricted share equivalents held by each of Messrs. Harris, Martinez and Zollars, Dr. Henney and Ms. Zarcone. The restricted share equivalents were granted in connection with the directors' election to the Board between 2004 and 2006. The restricted share equivalents and the restricted stock units have the same terms and conditions, except that, upon separation of service, the restricted share equivalents would have settled in cash and the restricted stock units will settle in shares of Cigna stock. The restricted stock units vest after nine years of service or upon reaching age 65. All restricted stock units are vested.
Hypothetical Shares of Common Stock (Column (d))
Column (d) includes (1) share equivalents resulting from voluntary deferrals of cash compensation hypothetically invested in the Cigna stock fund; (2) hypothetical shares of Cigna common stock credited to directors' restricted deferred compensation accounts under the terms of the retirement plan in effect between 1997 and 2005; and (3) hypothetical shares of Cigna common stock acquired pursuant to a pre-2006 requirement that directors invest or defer a portion of their Board retainer in shares of hypothetical Cigna common stock. Although these securities are not common stock, the value of the hypothetical shares of Cigna common stock credited to a director's deferred compensation account is tied directly to the value of Cigna common stock.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 39
|
COMPENSATION MATTERS
ADVISORY APPROVAL OF EXECUTIVE COMPENSATION (PROPOSAL 2)
Our Board is committed to strong governance and recognizes that Cigna shareholders have an interest in our executive compensation policies and practices. SEC rules require that we provide our shareholders with the opportunity to vote to approve, on an advisory basis, the compensation of our named executive officers (NEOs). In recognition of the preference of shareholders expressed at our 2011 Annual Meeting, the Board has adopted a policy that provides for annual "say on pay" advisory votes. Consistent with this policy and SEC rules, we are asking you to approve the following advisory resolution:
Resolved, that the shareholders approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement for the 2015 Annual Meeting of Shareholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, Executive Compensation Tables and accompanying narrative disclosure.
We believe that our executive compensation program design effectively aligns the interests of our executive officers with those of our shareholders by tying a significant portion of their compensation to Cigna's performance and rewarding our executive officers for the creation of long-term value for Cigna's shareholders. In considering your vote, we encourage you to review the Proxy Summary beginning on page 1, the CD&A beginning on page 41 and the Executive Compensation Tables beginning on page 73.
This advisory vote is intended to address our overall compensation policies and practices related to the NEOs, rather than any specific element of compensation. Because your vote is advisory, it will not be binding upon the Board. However, the Board and People Resources Committee value your opinion and will review and consider the voting results when making future executive compensation decisions.
The Board of Directors unanimously recommends that shareholders vote FOR advisory approval of the Company's executive compensation.
40
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
COMPENSATION DISCUSSION AND ANALYSIS
Cigna's executive compensation program is based on the philosophy that executive pay should strongly align with the interests of our shareholders, directly link to Company and individual performance, and attract and retain executive talent. We believe the achievement of our corporate goals will result in the creation of meaningful and sustained long-term value for our shareholders. The primary principles underlying our compensation philosophy are to:
This Compensation Discussion and Analysis (CD&A) describes the compensation policies, programs and decisions regarding our named executive officers (NEOs) for 2014.
Name |
Title |
|
||||
David M. Cordani | President and Chief Executive Officer | |||||
| Thomas A. McCarthy | Executive Vice President and Chief Financial Officer | | |||
Herbert A. Fritch | President, CignaHealthSpring | |||||
| Matthew G. Manders | President, U.S. Commercial Markets and Global Health Care Operations | | |||
Jason D. Sadler | President, International Markets | |||||
| | | | | | |
Company Performance |
Cigna's mission is to improve the health, well-being and sense of security of the people we serve in our more than 85 million customer relationships around the globe. This mission and focus on delivering value for our customers is at the center of what we do every day. Creating value for our customers, and in turn, our shareholders, is a direct result of the effective execution of our Go Deep, Go Global, Go Individual strategy that we implemented in 2010.
In 2014, Cigna delivered its fifth consecutive year of competitively attractive financial results. Consolidated revenue increased 8% over 2013 to $34.9 billion, with each business segment delivering strong growth. Consolidated adjusted income from operations* increased to $2.0 billion, compared with $1.93 billion for 2013. This reflects strong revenue growth, continued effective medical cost management and disciplined expense
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 41
|
COMPENSATION MATTERS (CONTINUED)
management. The following charts illustrate our revenue and adjusted income from operations growth, two key measures in determining the performance awards for our NEOs.
Consolidated Revenue (in billions) |
Consolidated Adjusted Income from Operations* (in billions) |
|
* We encourage you to review our Annual Report on Form 10-K for the year ended December 31, 2014 for more complete financial information. Consolidated adjusted income from operations is the principal measure we use to assess profitability but it is not a financial measure calculated in accordance with generally accepted accounting principles in the United States (GAAP). For a reconciliation of consolidated adjusted income from operations to the most directly comparable GAAP financial measure, which is shareholders' net income, see Annex A.
We believe that our success in executing our strategy in 2014 and during the past several years provides a strong foundation from which we can continue to deliver competitively attractive earnings and revenue growth to Cigna shareholders.
42
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
Total Shareholder Return and Relative Peer Performance |
The chart below shows the growth trend of a $100 investment in Cigna stock on December 31, 2011 over the past three years. For comparison purposes, we also have included the TSR of Cigna's 2014 peer group (see page 48) and the S&P 500 Index over the same time period.
Three Year Cumulative Total Shareholder Return*
December 31, 2011 December 31, 2014
* Assumes that the value of the investment in Cigna common stock and each index was $100 on December 31, 2011 and that all dividends were reinvested.
** Includes ACE, Aetna, AFLAC, Anthem, The Hartford Financial Services Group, HealthNet, Humana, Manulife Financial, MetLife and Unum Group. Market returns are weighted by relative market capitalization.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 43
|
COMPENSATION MATTERS (CONTINUED)
People Resources Committee Actions in 2014 |
In 2014, the People Resources Committee (the Committee) took a number of actions to support Cigna's business strategy that align with the Company's compensation objectives and reflect the strong financial results achieved in the fiscal year. We discuss each of these actions in greater detail elsewhere in this CD&A.
| | | | | | |
As part of the annual merit review process, increased 2014 base salaries for certain NEOs by an average of 7.5% over 2013 to better align the base salaries of certain NEOs with median market data, to reward individual performance and/or to reflect changes in role or responsibilities. | Page 52 | |||||
Awarded 2014 Management Incentive Plan (MIP) payouts to the NEOs ranging from 90% to 115% of target based on 2014 Company results and individual performance. |
Page 56 |
|
||||
Granted 2014 long-term incentive (LTI) awards to the NEOs ranging from 75% to 120% of target based on individual and business performance. |
Page 60 |
|||||
Approved the payout of the 2012-2014 strategic performance shares (SPSs) at 160% of target based on the Company's achievement of relative TSR and financial performance goals over the three-year period. |
Page 61 |
|
||||
In connection with organizational leadership changes, approved compensation adjustments and awards for Messrs. Manders and Sadler in recognition of their increased roles and responsibilities. |
Page 64 |
|||||
Reviewed and updated the peer groups to be used to evaluate executive officer compensation and determine LTI award performance beginning with 2015 compensation. |
Page 48 |
|
||||
Strengthened the focus on long-term profitable growth in the SPS program by tying performance in the 2015-2017 SPS program equally to adjusted income from operations and relative TSR, and removing revenue as a measure. This action also helped mitigate the use of duplicative measures in the Company's short- and long-term incentive plans. |
Page 62 |
|||||
| | | | | | |
Annual Shareholder Vote on Executive Compensation and Other Shareholder Feedback |
The Committee and the Board consider the results of the annual shareholder executive compensation say-on-pay vote, as well as other compensation-related shareholder votes, in determining the ongoing design and administration of the Company's executive compensation programs. At the 2014 annual meeting, shareholders overwhelmingly cast their advisory vote in favor of the 2013 compensation awarded to the Company's NEOs, with 94.7% of votes cast in favor. Notwithstanding these strong voting results, the Committee and the Board continued to make changes in 2014 designed to strengthen the Company's executive compensation programs, including:
44
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
The Committee also considers feedback on our executive compensation program received as part of our ongoing communications with shareholders. We believe that the tone of these communications has been positive, with broad shareholder support for our compensation practices.
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 45
|
COMPENSATION MATTERS (CONTINUED)
EXECUTIVE COMPENSATION POLICIES AND PRACTICES
Compensation Objectives and Practices |
Cigna's executive compensation program is based on the philosophy that executive pay should strongly align with the interests of our shareholders, directly link to Company and individual performance, and attract and retain executive talent. By emphasizing performance-based awards over fixed compensation, we strive to motivate superior enterprise results that we believe will result in the creation of meaningful and sustained long-term value for our shareholders.
To further our compensation philosophy, the Committee uses the following compensation practices, processes and instruments.
For information on the oversight of the executive compensation program, see Processes and Procedures for Determining Executive Compensation beginning on page 67.
46
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
Compensation Governance and Controls |
The Committee also regularly reviews executive compensation governance market trends when considering the adoption of new practices or changes to existing programs or policies.
Our governance practices and controls include:
These practices are described in more detail throughout this CD&A. For more information about the Committee's review of people development and succession planning and its role in risk oversight, see pages 28 and 68.
Market Data
The Committee establishes target compensation levels based on a variety of factors, including published information regarding the pay practices of the Company's peer group, as well as published survey and other data.
2014 Peer Group
For 2014 executive compensation decisions, the Committee continued to utilize the same peer group in effect for 2013 compensation decisions. The peer group was developed to include managed health care and multi-line insurance companies that have revenues and market capitalizations ranging from approximately one-half to two
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 47
|
COMPENSATION MATTERS (CONTINUED)
times Cigna's revenue and market capitalization, with Cigna's ranking near the median of this group. Screening also included a review of three-year TSR, three-year revenue, operating income and net income growth for these companies to determine whether Cigna's performance during the same period was near the median of the group. In addition to these quantitative measures, the Committee also considered qualitative factors, including identifying the companies against which Cigna competes for customers and talent and the presence of international operations.
The table below lists the companies included in the 2014 compensation peer group, as in effect for the December 2013 determination of the 2014 target pay mix and target total direct compensation, as well as the compensation adjustments in May 2014 for Messrs. Manders and Sadler in connection with their increased roles and responsibilities.
2014 Compensation Peer Group |
|
|||||
ACE Limited | Health Net, Inc. | |||||
| Aetna, Inc. | Humana, Inc. | | |||
Aflac Incorporated | Manulife Financial Corporation | |||||
| Anthem, Inc. | MetLife, Inc. | | |||
The Hartford Financial Services Group, Inc. | Unum Group | |||||
| | | | | | |
Benchmarking
In December 2013, the Committee changed its approach to the data it uses as the primary market reference for reviewing pay and setting target compensation levels. Historically, the Committee had relied on compensation data included in the proxy statements of companies in its peer group as the primary market reference. Where proxy data was not available, the Committee would review aggregate data from published surveys.
Upon the recommendation of its compensation consultant, the Committee shifted to using survey data exclusively as the primary market reference in determining base salary adjustments and compensation targets. Survey data, which is based on compensation information provided to third parties after proxy statements are filed, provides more current compensation information than proxy data. Proxy data is used to supplement the survey data if survey data is insufficient for a particular peer company. A broader cut of survey data, representing size-adjusted health and life insurance companies, was used to benchmark Mr. Sadler's compensation because peer group data was insufficient or unavailable for his specific role. A list of the companies used to benchmark Mr. Sadler's compensation is included on Annex B.
2015 Peer Groups
In 2014, the Committee requested that its independent compensation consultant conduct a review of the current peer group and offer suggested modifications for benchmarking future executive pay decisions. The Committee's consultant utilized multiple sources to recommend potential peer companies for the Committee to consider. Sources included a screening of companies by industry and scope, peer groups developed by proxy advisory firms, peers identified in various analyst reports and peers of companies in Cigna's 2014 peer group. As a result of this review, the Committee added Prudential Financial, Inc. to the peer group, effective for 2015.
The Committee recognized that Cigna often competes for talent from companies beyond that of its identified peer group. As a secondary reference to provide a broader perspective on market practices, the Committee developed a general industry peer group. The general industry peer group was developed by screening publicly traded, U.S.-based companies within relevant industry classifications. The list was then narrowed to companies whose revenues were within the range of 0.4 to 2.5 times that of Cigna and whose market capitalization was
48
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
within the range of 0.2 to 10 times that of Cigna. The screening process resulted in a group of 43 companies which the Committee approved as a general industry peer group. A list of the general industry peer companies is included on Annex C.
At the recommendation of the compensation consultant, the Committee also created a performance peer group to be used exclusively to track relative total shareholder return within the SPS program, effective for 2015. The Committee recognized that certain direct competitors may not have been included in the 2015 compensation peer group due to their relative size. While size is a relevant factor in determining a compensation peer group, it is less relevant when measuring performance. Other companies were included in the 2015 peer group because Cigna competes with them for talent; however, because of significant differences in business focus, these companies do not make good comparators for performance purposes. For these reasons, the Committee created an SPS performance peer group comprising the same companies in its 2015 compensation peer group, but adding UnitedHealth Group Incorporated and removing ACE Limited and Prudential Financial, Inc.
Target Total Direct Compensation and Target Pay Mix |
The Committee determines target total direct compensation and target pay mix using survey data as the primary market reference as described above and consistent with its principles that (1) performance-based compensation should be emphasized over fixed compensation; and (2) long-term incentives should be more heavily weighted than annual incentives. Actual compensation, however, is driven by Company performance.
Target total direct compensation consists of base salary, the annual incentive target and the long-term incentive target. On an annual basis, the Committee approves each of these amounts for each NEO and seeks to target an executive officer's total direct compensation in a "competitive range" of within plus or minus 15% of the 50th percentile of the survey data being used for comparison purposes.
While the Committee targets total direct compensation in the competitive range, there may be variation in the target pay mix such that target amounts for individual compensation elements may be above or below the competitive range for the individual element. Target total direct compensation for a NEO also may vary outside of the competitive range of the 50th percentile of the primary market reference due to factors such as performance, tenure in role, range of data within the applicable market reference and market and economic conditions. Internal pay comparisons among the NEOs are not generally considered for purposes of the Committee's determination of target pay mix and target total direct compensation.
The table below presents each primary element of compensation for the NEOs subject to annual review by the Committee and the position of target total direct compensation relative to market data. Target total direct compensation reflects the sum of annual base salary and the 2014 targets for the MIP and LTI programs.
|
NEO |
|
2014 Annual Base Salary ($) |
|
2014 MIP Target ($) |
|
2014 LTI Target ($) |
|
Target Total Direct Compensation ($) |
Target Total Direct Compensation Position to Market(1) |
||||||||
| | | | | | | | | | | | | | | | | | |
|
David M. Cordani |
1,155,000 | 1,800,000 | 9,000,000 | 11,955,000 | Within competitive range | ||||||||||||
|
Thomas A. McCarthy |
| 650,000 | | 600,000 | | 2,100,000 | | 3,350,000 | Within competitive range | | |||||||
|
Herbert A. Fritch(2) |
1,000,000 | 1,000,000 | 2,000,000 | 4,000,000 | Above competitive range | ||||||||||||
|
Matthew G. Manders(3) |
| 675,000 | | 750,000 | | 2,100,000 | | 3,525,000 | Within competitive range | | |||||||
|
Jason D. Sadler(4) |
574,860 | 474,884 | 950,000 | 1,999,744 | Within competitive range | ||||||||||||
| | | | | | | | | | | | | | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 49
|
COMPENSATION MATTERS (CONTINUED)
As illustrated in the charts below, performance-based compensation represents approximately 90% of Mr. Cordani's target total direct compensation, including 75% in long-term incentives and 15% in annual incentives. On average, performance-based compensation represents 77% of target total direct compensation for the other NEOs, including an average of 56% in long-term incentives and 21% in annual incentives. The percentages shown below are targets only and will not match the percentages calculable from the compensation amounts reflected in the Summary Compensation Table on page 73.
Tally Sheets |
The Committee reviews tally sheets for all of its executive officers, first when targets are being reviewed in December and again before annual compensation award decisions are made in February. Tally sheets summarize historical actual and target compensation, current target compensation opportunity, outstanding equity awards, retirement and deferred compensation values, and potential payouts upon termination of employment. The Committee believes that tally sheets are a useful reference tool to aid in its determination of whether compensation decisions are appropriate in the context of Cigna's compensation philosophy and performance. The Committee uses tally sheets solely as a reference, not as a determinant, when making executive compensation decisions.
50
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
Cigna's 2014 executive compensation program consists of the following elements:
Element |
Description |
|
||||
Base Salary | Represents the fixed portion of each NEO's total direct compensation package. | |||||
Annual Incentive |
Annual incentive awards under the MIP are based on the achievement of annual enterprise results relative to pre-established goals, as well as individual performance accomplishments and contributions. |
|
||||
Long-Term Incentives |
Cigna's long-term incentive program also is performance-based compensation. In accordance with Cigna's compensation strategy, the predominant portion of a NEO's compensation opportunity is tied to the long-term results of the Company. |
|||||
Retirement and Deferred Compensation |
Cigna provides retirement benefits in the United States that are aligned to competitive market practice, including 401(k) plans and a voluntary non-qualified deferred compensation program that does not have any Company contributions. Executive officers working outside of the United States receive comparable arrangements. U.S.-based NEOs hired before July 1, 2009 have accrued benefits from defined benefit pension plans that were frozen on July 1, 2009. |
|
||||
Limited Perquisites and Other Benefits |
Cigna provides limited perquisites to executive officers, which are designed to attract and retain key talent and provide for the safety and security of executive officers. Executive officers working outside of the United States also may be provided with local benefits that are customary in the country in which they are based. The NEOs are eligible to receive all of the benefits offered to Cigna employees generally, including medical benefits, other health and welfare benefits and other voluntary benefits. In addition, the CEO is encouraged to use the corporate aircraft for business and personal travel. |
|||||
| | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 51
|
COMPENSATION MATTERS (CONTINUED)
Base Salary |
Base salary represents only 10% of CEO target pay and an average of 23% for all other NEOs, with the balance of target compensation being performance-based compensation.
Base Salary Snapshot
2014 Base Salaries
The table below shows base salaries for each of the NEOs. Base salaries listed below may differ from the values reported in the Summary Compensation Table on page 73, due to the timing of changes to the NEOs' base salaries.
NEO |
2014 Annual Base Salary ($) |
|
||||
David M. Cordani | 1,155,000 | |||||
| Thomas A. McCarthy | 650,000 | | |||
Herbert A. Fritch(1) | 1,000,000 | |||||
| Matthew G. Manders(2) | 675,000 | | |||
Jason D. Sadler(2) | 574,860 | |||||
| | | | | | |
In February 2014, as part of the annual merit review process, the base salaries of Messrs. Cordani, McCarthy and Sadler were increased by an average of 7.5%. These merit increases were based on survey data available in December 2013 and individual performance assessments. As further described on page 64, in May 2014, the Committee approved a 15% and 6% increase in Messrs. Manders' and Sadler's respective base salaries in recognition of their increased roles and responsibilities.
52
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
Annual Incentives |
Corporate annual performance goals are pre-established and designed to align with and drive execution of the Company's business strategy. Because profitability is critical to the long-term success of the business, no incentive award payments are made unless the Company achieves a pre-defined level of adjusted income from operations.
Management Incentive Plan Snapshot
MIP Performance Measures and Goals
Each year, the Committee sets enterprise performance measures, weightings and goals for annual incentive awards based on Cigna's business priorities. The Committee works with its independent compensation consultant to evaluate the appropriateness of these measures and weightings and the degree of challenge in the MIP performance goals. The measures are designed to align with and drive execution of the Company's business strategy. More detailed information on these measures is included in the table on page 55.
| | | | | | | | |
|
Measure |
Weighting |
Rationale | | ||||
|
Adjusted income from operations |
50% |
Reinforces the importance of profitable growth across the enterprise. |
|||||
|
Revenue |
20% |
Focuses on enterprise growth, encourages business decisions that optimize results for the enterprise, promotes cross-selling efforts and collaboration across business units, and drives customer focus. |
|
||||
|
Operating expense ratio improvement |
20% |
Drives continued focus on delivering ongoing expense efficiency while furthering investment capacity for ongoing innovation. |
|||||
|
Net promoter score (NPS) |
10% |
Reinforces our focus on customer retention and loyalty by measuring customer perception on matters such as our reputation, brand, product, service, pricing and providers, all of which we believe are critical to Cigna's success. |
|
||||
| | | | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 53
|
COMPENSATION MATTERS (CONTINUED)
For each MIP goal other than NPS, the Committee specifies certain below target, target, above target and superior levels of performance. For NPS, performance is either at or below the target level. To aid the Committee in setting these performance targets, and to assess the reasonableness and rigor of those targets, the Committee's compensation consultant annually presents a comprehensive report to the Committee that evaluates Cigna's historical relationship between pay and performance in comparison with Cigna's peer group. The compensation consultant also reviews performance goals determined by the Committee in the context of historical performance and analyst expectations of future performance for Cigna and Cigna's peer group.
MIP Funding and Award Determination Process
The key considerations to funding the MIP and determining individual award amounts are discussed below.
Achieve Earnings Gate. The Committee believes that achieving Cigna's profitability goals is critically important to the long-term success of the business. In recognition of its importance, a pre-defined level of adjusted income from operations (the earnings gate) must be achieved in order for the Committee to fund the MIP. If the Company does not meet the earnings gate, the MIP will not be funded and no annual incentives will be paid to the NEOs. The earnings gate reflects the minimum acceptable level of financial performance relative to Cigna's corporate objectives for the year.
Company Performance Drives Funding Level. If the Company achieves the earnings gate, the Committee may fund the pool from 0% to 200% of target based upon with the following performance ranges: below target, target, above target and superior. The target performance range for the adjusted income from operations, revenue and operating expense improvement goals results in funding at 80% to 120% of target award levels. NPS performance at or above target results in funding at 100% to 200% of target award levels.
The Company's actual performance is the basis for establishing the range of funding available for awards. The Committee maintains the discretion to determine at which point within the limits of the pre-established range the actual funding will be set. In setting the actual funding, the Committee considers Cigna's performance as a whole (both in absolute terms and relative to competitors), as well as Cigna's achievement of the goals within each performance measure. The MIP funding mechanisms ensure that a minimum level of performance is achieved and that NEOs are rewarded for strong Company performance.
The Committee retains the flexibility to make incentive awards if target MIP goals are not achieved to aid in the retention of select key talent over the long-term and the encouragement of management to make decisions that could yield lesser results in the short-term, but are in the best interests of the Company's shareholders over the long-term.
54
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement |
COMPENSATION MATTERS (CONTINUED)
Award Amounts Based on Individual Contributions to Company Performance. Once MIP funding has been determined, the Committee (and for Mr. Cordani, the Board of Directors upon the recommendation of the Committee) assesses each executive officer's individual performance contributions and how such contributions impacted the achievement of the MIP goals to determine the actual award amounts for each NEO. Actual awards can range from 0% to 200% of a NEO's MIP target, allowing the Committee to differentiate based on overall performance.
2014 Performance Goals, Measures and Actual Results
For 2014, the Committee established the performance measures, weightings and target performance goals below, which were used to determine the range of potential aggregate funding for MIP awards.
Measure |
|
Weighting |
Target Performance Goals* |
Actual Result | | ||||||||
Adjusted income from operations** |
|
50% |
(2)% to 10% growth |
6.1% growth was within target range |
|
||||||||
|
The target was set as a year-over-year growth goal for Cigna's Global Health Care, Global Supplemental Benefits and Group Disability and Life segments. |
||||||||||||
Revenue |
|
20% |
4% to 10% growth |
8.2% growth was within target range |
|
||||||||
|
The target was set as a year-over-year growth goal for Cigna's Global Health Care, Global Supplemental Benefits and Group Disability and Life segments. |
||||||||||||
Operating expense ratio improvement |
|
20% |
(3.8)% to 0.3% improvement |
(1.0)% improvement was within target range |
|
||||||||
|
The target was set as a composite objective, which measures operating expense improvement in Cigna's Global Health Care, Global Supplemental Benefits and Group Disability and Life segments versus 2013. Operating expenses are expressed as a percent of revenue for each segment. As further described below, this target considers the impact of the health insurance industry tax. |
||||||||||||
Net promoter score (NPS) |
|
10% |
Improve or maintain 2013 NPS score |
2014 NPS score improved from 2013 |
|
||||||||
|
This is a measure of customer loyalty based on the results of externally conducted customer surveys. |
||||||||||||
|
The target was set as a composite objective, measuring the year-over-year improvement of the NPS against 2013 results. NPS results from each of Cigna's segments are weighted based on the Company's 2014 operating plan for the segment's premiums and fees to establish both the NPS baseline and final result for 2014. |
||||||||||||
| | | | | | | | | | | | | |
2015 Notice of Annual Meeting of Shareholders and Proxy
Statement 55
|
COMPENSATION MATTERS (CONTINUED)
In setting the target performance goals for each measure, the Committee considered Cigna's publicly disclosed earnings estimates, historical Company and peer company performance, analyst commentary and the Company's then-current expectations for the industry and economic environment. The Committee considered various market forces impacting the Company and related uncertainty, including the expectation that the industry would face significant market change and disruption in 2014. Factors contributing to this uncertainty included disruption in the Medicare Advantage market and the impact of the Affordable Care Act, which included uncertainty regarding enrollment and margins associated with the individual business on the public exchanges and the health insurance industry tax that was assessed for the first time in 2014. The Committee believed that the target performance goals represented competitively attractive goals, that would be challenging to achieve although not certain, in light of the circumstances facing the Company in 2014.
2014 Individual MIP Targets and Awards
MIP target levels for the 2014 performance year for the NEOs are set forth in the table below. In December 2013, the Committee approved a 12% increase in Mr. Sadler's 2014 MIP target to further incent him to achieve aggressive goals set for his business. In May 2014, in recognition of their increased roles and responsibilities, the Committee approved 30% and 6% increases to the 2014 MIP targets for Messrs. Manders and Sadler, respectively.
In determining actual MIP awards, the Committee (and for Mr. Cordani, the Board of Directors upon the recommendation of the Committee) takes an integrated approach, assessing enterprise results together with each executive officer's individual performance contributions during 2014. For the 2014 performance year, the Committee and the Board made annual incentive awards to the NEOs ranging from 90% to 115% of the target award value, as reflected in the following table.
NEO |
|
2014 MIP Target ($) |
|
MIP Maximum Award ($) |
Actual MIP Payout ($) |
Payout as a Percent of Target (%) |
| |||||||
David M. Cordani | 1,800,000 | 3,600,000 | 1,900,000 | 105.5 | ||||||||||
| Thomas A. McCarthy | | 600,000 | | 1,200,000 | 630,000 | 105 | | ||||||
Herbert A. Fritch(1) |